1
|
Cazzaniga ME, Pronzato P, Amoroso D, Bernardo A, Biganzoli L, Bisagni G, Blasi L, Bria E, Cognetti F, Crinò L, De Laurentiis M, Del Mastro L, De Placido S, Beano A, Ferraù F, Foladore S, Forcignanò R, Gamucci T, Garrone O, Gennari A, Giordano M, Giotta F, Giovanardi F, Latini L, Livi L, Marchetti P, Mattioli R, Michelotti A, Montemurro F, Putzu C, Riccardi F, Ricciardi G, Romagnoli E, Sarobba G, Spazzapan S, Tagliaferri P, Tinari N, Tonini G, Turletti A, Verusio C, Zambelli A, Mustacchi G. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study. Cancers (Basel) 2023; 16:117. [PMID: 38201545 PMCID: PMC10777910 DOI: 10.3390/cancers16010117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 11/14/2023] [Accepted: 12/08/2023] [Indexed: 01/12/2024] Open
Abstract
GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes-based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79-19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months-95% CI 5.7-9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7-15.1) and Luminal B patients (11.8 months, 95% CI 10.3-12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3-6.5 vs. Luminal A-9.4, 95% CI 8.1-10.7, and Luminal B-7.7 95% CI 6.8-8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8-37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2-31.2) and TNBC (18.5 months, 95% CI 16-20.1, F-ratio 7.44, p = 0.0006). The GIM 13-AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients.
Collapse
Affiliation(s)
- Marina Elena Cazzaniga
- Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy
- School of Medicine and Surgery, Università Milano Bicocca, 20900 Monza, Italy
| | - Paolo Pronzato
- Oncologia Medica IRCCS IRST San Martino, 16100 Genova, Italy; (P.P.); (L.D.M.)
| | - Domenico Amoroso
- Oncologia Medica, Ospedale Versilia USL Nord Ovest Toscana, 55041 Lido di Camaiore, Italy;
| | - Antonio Bernardo
- Oncologia Istituti Clinici Scientifici Maugeri Spa Società Benefit, 27100 Pavia, Italy;
| | - Laura Biganzoli
- U.O. Oncologia Medica, Ospedale Santo Stefano, 59100 Prato, Italy;
| | - Giancarlo Bisagni
- Oncologia Medica, IRCCS Arcispedale S. Maria Nuova, 42121 Reggio Emilia, Italy;
| | - Livio Blasi
- Oncologia Medica, ARNAS Civico–Di Cristina-Benfratelli, Presidio Ospedaliero ‘Civico e Benfratelli’, 20121 Palermo, Italy;
| | - Emilio Bria
- Oncologia Medica, A.O.U. Integrata Verona, Ospedale Borgo Roma, 37100 Verona, Italy;
| | - Francesco Cognetti
- Oncologia Medica 1, Istituto Nazionale Tumori “Regina Elena”, 00042 Roma, Italy
| | - Lucio Crinò
- Oncologia, Ospedale S. Maria della Misericordia, 06121 Perugia, Italy;
| | | | - Lucia Del Mastro
- Oncologia Medica IRCCS IRST San Martino, 16100 Genova, Italy; (P.P.); (L.D.M.)
| | - Sabino De Placido
- Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi Federico II, 80013 Napoli, Italy;
| | - Alessandra Beano
- Oncologia Medica, Città della Salute e della Scienza, ASL “Città di Torino”, 10024 Torino, Italy;
| | | | - Silva Foladore
- SSD Oncologica e dell’apparato Riproduttivo Femminile, Azienda Sanitaria Universitaria “Giuliano Isontina, 34121 Trieste, Italy;
| | | | | | - Ornella Garrone
- Oncologia Medica, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20100 Milano, Italy;
| | - Alessandra Gennari
- Oncologia Medica, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, Dipartimento di Medicina e Chirurgia, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy;
| | | | - Francesco Giotta
- Oncologia, IRCCS Istituto Tumori ‘Giovanni Paolo II’, 70100 Bari, Italy;
| | - Filippo Giovanardi
- UOS Day Hospital Oncologico, AUSL Reggio Emilia, Presidio Ospedaliero di Guastalla, 42016 Guastalla, Italy;
| | | | - Lorenzo Livi
- Dipartimento di Scienze Biomediche, Sperimentali e Cliniche ‘Mario Serio’, Università degli Studi di Firenze, UOC Radioterapia, A.O.U. Careggi, 50100 Firenze, Italy;
| | | | - Rodolfo Mattioli
- Oncologia Medica, A.O. Ospedali Riuniti Marche Nord-Ospedale Santa Croce, 61032 Fano, Italy
| | | | - Filippo Montemurro
- Fondazione del Piemonte per l’Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.), 10024 Torino, Italy;
| | - Carlo Putzu
- Oncologia Medica, AOU Sassari, 07100 Sassari, Italy
| | - Ferdinando Riccardi
- Oncologia Medica, Azienda Ospedaliera ‘A. Cardarelli’ (AORN), 80013 Napoli, Italy
| | | | | | - Giuseppina Sarobba
- Oncologia Medica, Ospedale ‘San Francesco’, Azienda Sanitaria Locale 3 Nuoro, 08100 Nuoro, Italy
| | - Simon Spazzapan
- Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy;
| | | | - Nicola Tinari
- Oncologia Medica, Policlinico ‘SS. Annunziata’, 66100 Chieti, Italy;
| | - Giuseppe Tonini
- Policlinico Universitario Campus Biomedico, 00042 Roma, Italy;
| | - Anna Turletti
- Presidio Ospedaliero Martini, ASL TO1, 10024 Torino, Italy
| | - Claudio Verusio
- Oncologia Medica, ASST della Valle Olona, Ospedale di Saronno, 21047 Saronno, Italy;
| | - Alberto Zambelli
- Oncologia Medica, ASST Papa Giovanni XXIII, Ospedale Papa Giovanni XXIII, 24100 Bergamo, Italy;
| | | |
Collapse
|
2
|
Caminiti C, Annunziata MA, Verusio C, Pinto C, Airoldi M, Aragona M, Caputo F, Cinieri S, Giordani P, Gori S, Mattioli R, Novello S, Pazzola A, Procopio G, Russo A, Sarobba G, Zerilli F, Diodati F, Iezzi E, Maglietta G, Passalacqua R. Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients With Cancer: The HuCare2 Stepped-Wedge Cluster Randomized Trial. JAMA Netw Open 2021; 4:e2128667. [PMID: 34648011 PMCID: PMC8517739 DOI: 10.1001/jamanetworkopen.2021.28667] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
IMPORTANCE Many patients with cancer who would benefit from psychosocial care do not receive it. Implementation strategies may favor the integration of psychosocial care into practice and improve patient outcomes. OBJECTIVE To evaluate the effectiveness of the Humanization in Cancer Care (HuCare) Quality Improvement Strategy vs standard care as improvement of at least 1 of 2 domains (emotional or social function) of patient health-related quality of life at baseline and 3 months. A key secondary aim included investigation of the long-term effect. DESIGN, SETTING, AND PARTICIPANTS HuCare2 was a multicenter, incomplete, stepped-wedge cluster randomized clinical trial, conducted from May 30, 2016, to August 28, 2019, in three 5-center clusters of cancer centers representative of hospital size and geographic location in Italy. The study was divided into 5 equally spaced epochs. Implementation sequence was defined by a blinded statistician; the nature of the intervention precluded blinding for clinical staff. Participants included consecutive adult outpatients with newly diagnosed cancer of any type and stage starting medical cancer treatment. INTERVENTIONS The HuCare Quality Improvement Strategy comprised (1) clinician communication training, (2) on-site visits for context analysis and problem-solving, and (3) implementation of 6 evidence-based recommendations. MAIN OUTCOMES AND MEASURES The primary outcome was the difference between the means of changes of individual scores in emotional or social functions of health-related quality of life detected at baseline and 3-month follow-up (within each group) and during the postintervention epoch compared with control periods (between groups). Long-term effect of the intervention (at 12 months) was assessed as a secondary outcome. Intention-to-treat analysis was used. RESULTS A total of 762 patients (475 [62.3%] women) were enrolled (400 HuCare Quality Improvement Strategy and 362 usual care); mean (SD) age was 61.4 (13.1) years. The HuCare Quality Improvement Strategy significantly improved emotional function during treatment (odds ratio [OR], 1.13; 95% CI, 1.04-1.22; P = .008) but not social function (OR, 0.99; 95% CI, 0.89-1.09; P = .80). Effect on emotional function persisted at 12 months (OR, 1.05; 95% CI, 1.00-1.10; P = .04). CONCLUSIONS AND RELEVANCE In this trial, the HuCare Quality Improvement Strategy significantly improved the emotional function aspect of health-related quality of life during cancer treatment and at 12 months, indicating a change in clinician behavior and in ward organization. These findings support the need for strategies to introduce psychosocial care; however, more research is needed on factors that may maximize the effects. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03008993.
Collapse
Affiliation(s)
- Caterina Caminiti
- Research and Innovation Unit, University Hospital of Parma, Parma, Italy
| | | | - Claudio Verusio
- Department of Oncology, ASST Valle Olona, Busto Arsizio, Varese, Italy
| | - Carmine Pinto
- Medical Oncology Unit, Clinical Cancer Center, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy
| | - Mario Airoldi
- Second Medical Oncology Division, AOU Città della Salute e della Scienza of Turin, Turin, Italy
| | - Marcello Aragona
- Medical Oncology Unit, Department of Human Pathology of Adult and Evolutive Age, University of Messina, Messina, Italy
| | | | - Saverio Cinieri
- Oncology Unit, San Antonio Perrino Hospital, Brindisi, Italy
| | - Paolo Giordani
- Medical Oncology Unit, Ospedali Riuniti Marche Nord, Pesaro and Fano, Italy
| | - Stefania Gori
- Medical Oncology Division, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy
| | - Rodolfo Mattioli
- Medical Oncology Unit, Ospedali Riuniti Marche Nord, Pesaro and Fano, Italy
| | - Silvia Novello
- Department of Oncology, University of Turin, AOU San Luigi Orbassano, Italy
| | - Antonio Pazzola
- Medical Oncology Unit, University-Hospital of Sassari, Sassari, Italy
| | - Giuseppe Procopio
- Department of Medical Oncology, National Cancer Institute of Milan, Milan, Italy
| | - Antonio Russo
- Medical Oncology Unit, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Giuseppina Sarobba
- Oncology Unit, San Francesco Hospital, ATS Sardegna ASSL Nuoro, Nuoro, Italy
| | | | - Francesca Diodati
- Research and Innovation Unit, University Hospital of Parma, Parma, Italy
| | - Elisa Iezzi
- Research and Innovation Unit, University Hospital of Parma, Parma, Italy
| | - Giuseppe Maglietta
- Research and Innovation Unit, University Hospital of Parma, Parma, Italy
| | - Rodolfo Passalacqua
- Medical Oncology Division, Department of Oncology, ASST of Cremona, Cremona, Italy
| |
Collapse
|
3
|
Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. JAMA Oncol 2020; 6:547-551. [PMID: 32053133 DOI: 10.1001/jamaoncol.2019.6486] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Importance The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival. The Three or Six Colon Adjuvant (TOSCA) trial compared 3 months with 6 months of adjuvant fluoropyrimidine and oxaliplatin-based chemotherapy in patients with stage III colon cancer. The utility remains unknown. Objective To assess the noninferiority and toxic effects of 3 vs 6 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) adjunct chemotherapy among patients with high-risk stage II resected colorectal cancer enrolled in the TOSCA trial. Design, Setting, and Participants The TOSCA study was a noninferiority phase 3 randomized clinical trial conducted from June 2007 to March 2013 in 130 Italian centers. Included patients had resected colorectal cancer located 12 cm from the anal verge by endoscopy or above the peritoneal reflection at surgery. In this preplanned study assessing the per-protocol population, 5-year relapse-free survival was evaluated in 1254 patients with high-risk stage II resected colorectal cancer who had received adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin). Interventions Patients were originally randomized (1:1) in the TOSCA trial to receive 3 months (experimental group) or 6 months (control) of standard doses of FOLFOX or CAPOX at the discretion of the treating physician. Main Outcome and Measures A hazard ratio of at least 1.2 between the 3-month and 6-month chemotherapy groups was set to reject the null hypothesis of noninferiority. Results Overall, 1254 patients (mean [SD] age, 62.4 [9.8] years; 565 women [45.1%]) with clinical high-risk stage II resected colorectal cancer were analyzed at a median follow-up of 62 months (interquartile range, 53-71) months. Of them, 301 patients (24.0%) had pT4N0M0 tumors, and the remaining 953 patients (76.0%) had high-risk pT3N0M0 tumors; 776 patients (61.9%) received FOLFOX and 478 (38.1%) received CAPOX. The 5-year relapse-free survival was 82.2% for the 3-month arm and 88.2% for the 6-month arm, with an estimated hazard ratio of 1.41 (95% CI, 1.05-1.89; P = .86 for noninferiority). For CAPOX, the 5-year relapse-free survival was similar in the 2 arms (difference, 0.76% favoring the 6-month arm; 95% CI, -6.28% to 7.80%), whereas for FOLFOX, the difference was pronounced: 8.56% in favor of the longer-duration arm (95% CI, 3.45%-13.67%). Nevertheless, the test for an interaction between duration and regimen was not statistically significant. Neurotoxicity was approximately 5 times lower in the shorter duration arm than in the longer duration arm. Conclusions and Relevance In the 3-month arm, the treatment was significantly less toxic than in the 6-month arm. Noninferiority was not shown for 5-year relapse-free survival. However, a possible regimen effect was observed, suggesting that either 3 months of CAPOX or 6 months of FOLFOX therapy can be used whenever an oxaliplatin doublet is indicated for treatment of patients with stage II colorectal cancer. Trial Registration ClinicalTrials.gov Identifier: NCT0064660.
Collapse
Affiliation(s)
- Fausto Petrelli
- Medical Oncology Unit, Medical Science Department, American SamoaST Bergamo Ovest, Treviglio (BG), Italy
| | | | | | - Sara Lonardi
- Medical Oncology Unit 1, Istituto Oncologico Veneto-IRCCS, Padova, Italy
| | - Fabio Galli
- Laboratory of Clinical Research Methodology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy
| | - Eliana Rulli
- Laboratory of Clinical Research Methodology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy
| | - Gerardo Rosati
- Medical Oncology Unit, Ospedale San Carlo, Potenza, Italy
| | - Salvatore Corallo
- Medical Oncology Unit, Fondazione Istituto Nazionale Tumori-IRCCS, Milano, Italy
| | - Monica Ronzoni
- Medical Oncology Unit, Ospedale San Raffaele-IRCCS, Milano, Italy
| | | | - Rodolfo Mattioli
- Medical Oncology Unit, Azienda Ospedaliera Santa Croce, Fano, Italy
| | - Andrea Mambrini
- Medical Oncology Unit Massa Carrara, Azienda Toscana Nordovest, Italy
| | - Libero Ciuffreda
- Medical Oncology Unit, Azienda Ospedaliero Universitaria San Giovanni Battista, Molinette, Torino, Italy
| | - Maria Banzi
- Medical Oncology Unit, AUSL-IRCCS, Reggio Emilia, Italy
| | - Valeria Pusceddu
- Medical Oncology, University Hospital and University of Cagliari, Cagliari, Italy
| | - Evaristo Maiello
- Medical Oncology Unit, Hospital Casa Sollievo della Sofferenza-IRCCS, San Giovanni Rotondo, Italy
| | - Maria Zampino
- Gastrointestinal Medical Oncology Unit and Neuroendocrine Tumors, Istituto Europeo di Oncologia-IRCCS, Milano, Italy
| | - Vittorina Zagonel
- Medical Oncology Unit 1, Istituto Oncologico Veneto-IRCCS, Padova, Italy
| | - Paolo Marchetti
- Medical Oncology Unit, Sant'Andrea Hospital, Sapienza University of Rome and IDI-IRCCS, Roma, Italy
| | - Domenico Corsi
- Medical Oncology Unit Azienda Ospedaliera San Giovanni Calibita Fatebenefratelli Roma, Italy
| | - Lorenza Rimassa
- Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, Rozzano (Milano), Italy
| | - Saverio Cinieri
- Medical Oncology Unit, Ospedale di Summa A. Perrino Brindisi, Italy
| | | |
Collapse
|
4
|
Bracci R, Gasperini B, Capalbo M, Campanelli T, Caimmi E, Mattioli R, Espinosa E, Prospero E. How to improve the identification of patients with cancer eligible for genetic counselling? Eur J Cancer Care (Engl) 2020; 29:e13276. [DOI: 10.1111/ecc.13276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Revised: 02/09/2020] [Accepted: 04/16/2020] [Indexed: 11/27/2022]
Affiliation(s)
- Raffaella Bracci
- Oncology Unit Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro Italy
| | - Beatrice Gasperini
- Geriatric Unit Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro Italy
| | - Maria Capalbo
- Direzione Generale Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro Italy
| | - Tamara Campanelli
- Oncology Unit Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro Italy
| | - Eleonora Caimmi
- Section of Hygiene Department of Biomedical Sciences Università Politecnica delle Marche Ancona Italy
| | - Rodolfo Mattioli
- Oncology Unit Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro Italy
| | - Emma Espinosa
- Geriatric Unit Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro Italy
| | - Emilia Prospero
- Section of Hygiene Department of Biomedical Sciences Università Politecnica delle Marche Ancona Italy
| |
Collapse
|
5
|
Iacovelli R, Buti S, Buttigliero C, De Vivo R, Caserta C, Ferraú F, Galli L, Martelli V, Masini C, Mattioli R, Merler S, Milesi L, Naglieri E, Ricotta R, Rizzo M, Sacco C, Santini D, Tambaro R, Verri E, Santoni M. Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.6_suppl.tps596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS596 Background: Urothelial cancer (UC) is the ninth most common cancer worldwide, this tumour has a poor prognosis when in advanced stage. Cisplatin-based chemotherapy is considered the most effective treatment but more than 50% of patients are considered not eligible ( cis-unfit) for this regimen and have a median survival of only 6-9 months. In the past years, the most used chemotherapy regimen for cis-unfit patients was the combination of carboplatin and gemcitabine. Two single arm studies tested the anti-PD-L1/PD1 monoclonal antibodies atezolizumab and pembrolizumab and reported a response rate of 25% with good safety profile in an unselected population for PD-L1 expression. Recently, atezolizumab alone showed longer OS compared to carboplatin-gemcitabine regimen. Avelumab is another fully human anti-PD-L1 IgG1 antibody already tested in urothelial and in other cancers with a promising safety and efficacy profile. Methods: The single arm, phase II ARIES trial (NCT03891238), aims to evaluate the activity and efficacy of avelumab in patients with metastatic or locally advanced UC considered cis-unfit with PD-L1 expression ≥5%. Overall survival is the primary endpoint. Cis-unfit definition includes at least one of the following characteristics (i) ECOG-Performance status=2; (ii) creatinine clearance <60 ml/min; (iii) grade ≥2 peripheral neuropathy or hearing loss; (iv) disease progression within six months after a previous adjuvant/neoadjuvant treatment with cisplatin-based therapy. Avelumab will be administered at standard dose of 10 mg/kg in 1-hour intravenous infusion every 2 weeks (Q2W). Sixty-seven patients will be enrolled, and supportive care is allowed during the study. Avelumab may be continued after radiological progression of disease at physician’s discretion if an improvement of symptoms or not new symptoms will be reported. The study is currently ongoing in twenty centres in Italy. Clinical trial information: NCT03891238.
Collapse
Affiliation(s)
| | - Sebastiano Buti
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy
| | - Consuelo Buttigliero
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy
| | | | | | - Francesco Ferraú
- Medical Oncology Department, Ospedale S Vincenzo, Taormina, Italy
| | - Luca Galli
- Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
| | - Valentino Martelli
- Medical Oncology Unit 1, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genova, Italy
| | - Cristina Masini
- Medical Oncology Unit, IRCCS-Arcispedale S. Maria Nuova, Reggio Emilia, Italy
| | | | - Sara Merler
- Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
| | - Laura Milesi
- Oncologia Medica Asst Papa Giovanni XXIII, Bergamo, Italy
| | - Emanuele Naglieri
- Division of Medical Oncology, Istituto Tumori Bari Giovanni Paolo II - IRCCS, Bari, Italy
| | | | - Mimma Rizzo
- Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy
| | - Cosimo Sacco
- Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria S. M. della Misericordia, Udine, Italy
| | - Daniele Santini
- Department of Medical Oncology, Campus Bio-Medico-University of Rome, Rome, Italy
| | - Rosa Tambaro
- Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy
| | - Elena Verri
- Medical Oncology Division of Urogenital and Head and Neck Tumors. European Institute of Oncology, Milan, Italy
| | - Matteo Santoni
- Medical Oncology Unit, Macerata General Hospital, Macerata, Italy
| |
Collapse
|
6
|
Rosati G, Galli F, Cantore M, Bergamo F, Banzi M, Zampino MG, Mattioli R, Cardellino GG, Ronzoni M, Di Bartolomeo M, Tamberi S, Marchetti P, Rimassa L, Corsi D, Bochicchio AM, Artioli F, Labianca R, Galli F, Rulli E, Bilancia D, Bregni G. Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. Oncologist 2020; 25:e928-e935. [PMID: 31943506 DOI: 10.1634/theoncologist.2019-0736] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 12/19/2019] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Although American Society of Clinical Oncology and European Society for Medical Oncology guidelines have identified the negative prognostic factors that clinicians have to consider when treating their patients with stage II colon cancer (CC), the role of histological subtype is controversial. SUBJECTS, MATERIALS, AND METHODS The randomized, multicenter, phase III TOSCA trial compared 3 versus 6 months of fluoropyrimidine-oxaliplatin adjuvant chemotherapy in 3,759 patients with high-risk stage II or stage III CC. The objective of this substudy was to evaluate the influence of histological subtypes on the impact of the treatment duration of adjuvant chemotherapy in terms of relapse-free survival (RFS) and overall survival (OS) in 85 mucinous adenocarcinoma (MUC) and 389 nonmucinous adenocarcinoma (NMUC) patients with high-risk stage II, grade 3 CC. RESULTS A significant interaction between treatment duration and histology was observed in both RFS (p = .027) and OS (p = .017). In the subgroup of patients with MUC, worse RFS (adjusted hazard ratio [HR], 3.95; 95% confidence interval [CI], 1.03-15.17; p = .045) and OS (HR, 9.56; 95% CI, 1.14-79.98; p = .037) were detected for patients treated in the 3-month arm. No statistically significant differences were found in the subgroup of patients with NMUC. CONCLUSION Patients with MUC, grade 3, stage II CC require special attention and may need 6 months of oxaliplatin-based chemotherapy. Larger studies are required to assess the combined use of histology and other prognostic/predictive factors to define the administration of chemotherapy in patients with stage II CC and to improve their prognosis. IMPLICATIONS FOR PRACTICE Although ASCO and ESMO guidelines define the prognostic factors for patients with stage II colon cancer to establish the use of adjuvant chemotherapy, the influence of histological subtypes is controversial in this population. This study underscores that patients with grade 3 mucinous adenocarcinomas may need adjuvant chemotherapy with oxaliplatin and fluoropyrimidines for a duration of 6 months rather than 3 months.
Collapse
Affiliation(s)
- Gerardo Rosati
- U.O. Oncologia Medica, Ospedale S. Carlo, Potenza, Italy
| | - Fabio Galli
- Methodology for Clinical Research Laboratory, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Maurizio Cantore
- U.O. Oncologia Medica, Azienda USL 1 di Massa e Carrara, Carrara, Italy
| | - Francesca Bergamo
- U.O. Oncologia Medica 1, IRCCS Istituto Oncologico Veneto, Padova, Italy
| | - Maria Banzi
- U.O. Oncologia Medica, Azienda USL-IRCCS, Reggio Emilia, Italy
| | - Maria Giulia Zampino
- Gastrointestinal Medical Oncology Unit and Neuroendocrine Tumors, IRCCS Istituto Europeo di Oncologia, Milan, Italy
| | - Rodolfo Mattioli
- U.O. Oncologia Medica, Azienda Ospedaliera Marche Nord, Pesaro/Fano, Italy
| | | | - Monica Ronzoni
- U.O. Oncologia Medica, Ospedale San Raffaele, Milan, Italy
| | | | - Stefano Tamberi
- U.O. Oncologia Medica, Ospedale degli Infermi, Faenza, Italy
| | - Paolo Marchetti
- U.O. Oncologia Medica, Ospedale Sant'Andrea, Università Sapienza, Roma e IRCCS Istituto Dermopatico dell'Immacolata, Rome, Italy
| | - Lorenza Rimassa
- Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy
| | - Domenico Corsi
- U.O. Oncologia Medica, Ospedale S. Giovanni Calibita Fatebenefratelli, Rome, Italy
| | - Anna Maria Bochicchio
- U.O. Oncologia Medica, Ospedale Oncologico Regionale CROB, Rionero in Vulture, Italy
| | | | | | - Francesca Galli
- Methodology for Clinical Research Laboratory, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Eliana Rulli
- Methodology for Clinical Research Laboratory, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | | | - Giacomo Bregni
- U.O. Oncologia Medica, IRCCS San Martino-IST, Genova, Italy
| |
Collapse
|
7
|
Rosati G, Galli F, Cantore M, Lonardi S, Banzi M, Zampino M, Mattioli R, Pella N, Ronzoni M, Bartolomeo MD, Tamberi S, Marchetti P, Bozzarelli S, Corsi D, Bochicchio A, Artioli F, Labianca R, Galli F, Bilancia D, Bregni G. Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Passalacqua R, Iezzi E, Annunziata MA, Verusio C, Pinto C, Airoldi M, Aragona M, Caputo F, Cinieri S, Giordani P, Gori S, Mattioli R, Novello S, Pazzola A, Procopio G, Russo A, Sacco C, Sarobba G, Zerilli F, Caminiti C. Integrating psychosocial care into routine cancer care: A stepped-wedge design cluster randomized controlled trial (SWD-RCT) to evaluate effectiveness of the HuCare Quality Improvement Strategy (HQIS) on health-related quality of life (HRQoL). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.6515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6515 Background: Cancer patients (pts) often do not receive evidence-based psychosocial care. We evaluate the effects of an implementation strategy we previously demonstrated feasible, which includes communication skill training for all physicians and nurses; four support visits at the centers by an improvement team to assist staff in identifying obstacles, finding solutions, and strengthening motivation; screening for distress and social needs; individualized pts' education with a referring nurse; use of a question prompt list. Methods: Multicenter incomplete SWD-RCT with 3 clusters of 5 centers each. Consecutive outpatients requiring medical treatment and diagnosed in the previous 2 months were eligible. Primary endpoint: difference of at least one of the 2 domains of HRQoL emotional or social functions, at 3 months from baseline, in pts of the centers that implemented the HQIS vs standard of care (SoC). Secondary endpoints include: patient mood, long-term effect, overall HRQoL. Analyses were performed using a beta-binomial regression model. Results: 762 pts were enrolled. At baseline, 41% showed high anxiety (HADS-A>7), and 88% had at least one psychosocial need. 299 health professionals attended 3-day courses (84% of all clinical staff). 647 pts (85%) were available for analysis. The 315 pts who received HQIS exhibited better quality of life for the emotional domain than those assigned to SOC (OR=1.115, p=0.016). Pts who showed the greatest improvement were the older (OR=1.003, p=0.035), had lower anxiety basal levels (OR=0.853, p<0.001), and social needs were met (OR=1.182, p<0.001). The difference was not significant for the social domain (OR=0.955, p=0.353). The HQIS’s long-term effect was confirmed for the emotional domain at 12 months. No effect on mood (HADS-D) and overall HRQoL was observed. Conclusions: To our knowledge this is the first RCT demonstrating the effectiveness of a psychosocial care implementation strategy on cancer patients’ emotional well-being. Clinical trial information: NCT03008993.
Collapse
Affiliation(s)
| | - Elisa Iezzi
- Azienda Ospedaliero Universitaria, Parma, Italy
| | | | - Claudio Verusio
- Department of Oncology, ASST Valle Olona, Busto Arsizio, Italy
| | - Carmine Pinto
- Medical Oncology Unit. Clinical Cancer Center. AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - Mario Airoldi
- 2nd Medical Oncology Division, A. O. Città della Salute e della Scienza di Torino, Torino, Italy
| | | | | | - Saverio Cinieri
- European Institute of Oncology (IRCCS), Milan, and San Antonio Perrino Hospital, Brindisi, Italy
| | | | - Stefania Gori
- Oncology Unit, Ospedale Sacro Cuore-don Calabria, Negrar, Italy
| | | | - Silvia Novello
- Department of Oncology, University of Turin, Orbassano, Italy
| | - Antonio Pazzola
- Medical Oncology - Ospedale Civile SS. Annunziata, Sassari, Italy
| | - Giuseppe Procopio
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - Antonio Russo
- Unit of Medical Oncology - Department of Oncology - AOUP, Palermo, Italy
| | - Cosimo Sacco
- Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria S. M. della Misericordia, Udine, Italy
| | - Giuseppina Sarobba
- "UOC Oncologia Ospedale San Francesco ATS Sardegna ASSL Nuoro", Nuoro, Italy
| | | | | | | |
Collapse
|
9
|
Fernandes CEM, Serafim KR, Gianlorenço ACL, Mattioli R. Systemic injection of an H4 receptor agonist induces a decrease in CREB and pCREB levels in the cerebellar vermis and prefrontal cortex in mice. ACTA ACUST UNITED AC 2019; 52:e8334. [PMID: 31038580 PMCID: PMC6487739 DOI: 10.1590/1414-431x20198334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Accepted: 03/07/2019] [Indexed: 11/21/2022]
Abstract
Studies have shown that an injection with the histamine H4 receptor agonist VUF-8430 modulates emotional memory processes. In the present study, the aim was to verify if intraperitoneal (ip) injection of VUF-8430 (500 ng/kg) in mice affects the synthesis of proteins required for memory consolidation processes by activating the phosphorylation of CREB (pCREB) in classical structures linked to emotional memory (prefrontal cortex, amygdala, and hippocampus) and the cerebellar vermis, a structure that has also been recently implicated in emotional memory. The results obtained using western blot analysis demonstrated that VUF-8430 induced a decrease in CREB and pCREB levels in the cerebellar vermis and prefrontal cortex, suggesting that this dose impaired the activation of cell signaling pathways in these structures. There was no change in protein expression in the amygdala and hippocampus. Our results are preliminary, and further investigations are needed to investigate the role of the H4 receptors in the central nervous system.
Collapse
Affiliation(s)
- C E M Fernandes
- Laboratório de Neurociência, Departamento de Fisioterapia, Centro de Biologia, Ciências e Saúde, Universidade Federal de São Carlos, São Carlos, SP, Brasil
| | - K R Serafim
- Laboratório de Neurociência, Departamento de Fisioterapia, Centro de Biologia, Ciências e Saúde, Universidade Federal de São Carlos, São Carlos, SP, Brasil
| | - A C L Gianlorenço
- Laboratório de Neurociência, Departamento de Fisioterapia, Centro de Biologia, Ciências e Saúde, Universidade Federal de São Carlos, São Carlos, SP, Brasil
| | - R Mattioli
- Laboratório de Neurociência, Departamento de Fisioterapia, Centro de Biologia, Ciências e Saúde, Universidade Federal de São Carlos, São Carlos, SP, Brasil
| |
Collapse
|
10
|
Imperatori L, Giardini D, Latini G, Migliori G, Blasi C, Bunkheila F, Breschi C, Mattioli R, Pelliccioni S, Laurino C, Vadalà M, Palmieri B, Iannitti T. Feasibility single-arm study of a medical device containing Desmodium adscendens and Lithothamnium calcareum combined with chemotherapy in head and neck cancer patients. Cancer Manag Res 2018; 10:5433-5438. [PMID: 30519091 PMCID: PMC6234998 DOI: 10.2147/cmar.s165746] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Background Neoplasms of the head and neck represent approximately 5% of cancers and they require complex multidisciplinary clinical management. Desmodium adscendens (Desmodium) is a plant that possesses anti-allergic, antioxidant and hepatoprotective properties. Lithothamnium calcareum (Lithothamnium) is a calcified seaweed that possesses remineralization properties and the ability to maintain homeostasis. Aim In this single-arm study, we investigated the efficacy of a combination therapy based on Desmovit® which contains Desmodium and Lithothamnium, and chemotherapy in patients with head and neck cancer. Methods Twelve patients with histological or cytological diagnosis of stage IV head and neck cancer were enrolled in this study that was approved by the ethics committee of the Unità Operativa Complessa (UOC) di Oncologia Medica Azienda Ospedaliera Ospedali Riuniti Marche Nord and followed the Declaration of Helsinki guidelines. The patients were monitored by investigation of the performance status according to the Glasgow Prognostic Score (GPS), which evaluates the plasma level of C-reactive protein and albumin levels, and the Eastern Cooperative Oncology Group (ECOG) examination. Pain and fatigue were also monitored using the visual analog scale and visual analog fatigue scale, respectively. All the above parameters were assessed biweekly to week 10. Results GPS, ECOG, and albumin remained stable throughout the study with a trend towards a decrease in GPS and albumin at week 10 post-treatment. Pain significantly improved at week 8 (P<0.05) while fatigue improved at weeks 8 and 10 (all P<0.01). Conclusion We found that chemotherapy, combined with Desmodium and Lithothamnium, improved pain and fatigue in head and neck cancer patients, although we cannot confirm if this was due to Desmodium and Lithothamnium or chemotherapy. The improvement in pain and fatigue was supported by the ECOG performance status remaining stable with the highest score being equal to 2 throughout the study and a trend towards an improvement in GPS performance status and albumin levels.
Collapse
Affiliation(s)
- Luca Imperatori
- UOC Oncologia Medica Azienda Ospedaliera Ospedali Riuniti Marche Nord, Fano, Italy
| | - Damiano Giardini
- UOC Otorinolaringoiatria Az. Ospedaliera Ospedali Riuniti Marche Nord, Fano, Italy
| | - Gino Latini
- UOC Otorinolaringoiatria Az. Ospedaliera Ospedali Riuniti Marche Nord, Fano, Italy
| | - Giuseppe Migliori
- UOC Otorinolaringoiatria Az. Ospedaliera Ospedali Riuniti Marche Nord, Fano, Italy
| | - Claudio Blasi
- UOC Radioterapia Az. Ospedaliera Ospedali Riuniti Marche Nord, Fano, Italy
| | - Feisal Bunkheila
- UOC Radioterapia Az. Ospedaliera Ospedali Riuniti Marche Nord, Fano, Italy
| | - Cesare Breschi
- UOC Anestesia e Rianimazione Az. Ospedaliera Ospedali Riuniti Marche Nord, Fano, Italy
| | - Rodolfo Mattioli
- UOC Oncologia Medica Azienda Ospedaliera Ospedali Riuniti Marche Nord, Fano, Italy
| | - Silvia Pelliccioni
- UOC Oncologia Medica Azienda Ospedaliera Ospedali Riuniti Marche Nord, Fano, Italy
| | - Carmen Laurino
- Department of General Surgery and Surgical Specialties, Surgical Clinic, University of Modena and Reggio Emilia Medical School, Modena, Italy
| | - Maria Vadalà
- Department of General Surgery and Surgical Specialties, Surgical Clinic, University of Modena and Reggio Emilia Medical School, Modena, Italy
| | - Beniamino Palmieri
- Department of General Surgery and Surgical Specialties, Surgical Clinic, University of Modena and Reggio Emilia Medical School, Modena, Italy
| | | |
Collapse
|
11
|
Catalano V, Bergamo F, Cremolini C, Vincenzi B, Negri F, Giordani P, Santini D, Sarti D, Torresi U, Bisonni R, Silva R, Rocchi M, Lonardi S, Falcone A, Mattioli R, Graziano F. Optimizing the use of first-line chemotherapy in metastatic colorectal cancer patients with mucinous histology. A multicenter, retrospective, combined analysis on 897 patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy150.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Silva RR, Bascioni R, Rossini S, Zuccatosta L, Mattioli R, Pilone A, Delprete S, Battelli N, Gasparini S, Battelli T. A Phase II Study of Mitomycin C, Vindesine and Cisplatin Combined with Alpha Interferon in Advanced Non-Small Cell Lung Cancer. Tumori 2018; 82:68-71. [PMID: 8623510 DOI: 10.1177/030089169608200115] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and background MVP chemotherapy (mitomycin C, vindesine or vinblastine, cisplatin) is one of the most commonly used regimens for advanced non-small cell lung cancer (NSCLC). Experimental data suggest a synergistic cytotoxic activity of alpha-interferon (α-IFN) when combined with cisplatin, mitomycin C, and vinca alkaloids. In an effort to improve MVP chemotherapy activity, we have combined this regimen with α-IFN. Patients and methods Thirty-five patients with advanced NSCLC (19 stage IV) were treated with the MVP regimen (mitomycin C, 8 mg/m2; vindesine, 3 mg/m2; cisplatin, 75 mg/m2, all on day 1) plus α-2a-IFN, 3×106 U im from day 1 to 7. The cycles were repeated every 28 days. Results There were no complete responses and 18 partial responses, for an overall response rate of 51%. Median time to treatment failure was 6 months (range, 1-18), and median survival was 9.5 months (range, 1-32). WHO grade 3 toxicity was recorded in up to 8% of patients, flu-like syndrome was a common complaint; one toxic death occurred. Conclusions The combination yielded a level of response comparable to that of other cisplatin-based regimens. Larger randomized trials are needed to assess the role of α-IFN combined with chemotherapy in advanced NSCLC.
Collapse
Affiliation(s)
- R R Silva
- Oncology Unit, Ospedale ¿Profili¿, Fabriano (An), Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
A new automatic perimeter has recently been developed under the supervision of the Perimetry Study Group of the Genoa University Eye Clinic. The main characteristics of this instrument are the following: projected targets; accurate calibration of stimulus size and shape; preliminary measurement of visual acuity and pupillary diameter; automated fixation control based on an optimized television system; static, kinetic, and mixed procedures; screening and diagnostic threshold and suprathreshold strategies; standard and non-standard parameters for stimuli, background, and procedures; user-friendly software; large disk memory for data storage and analysis.
Collapse
|
14
|
Abstract
At the Rizzoli Orthopaedic Institute, as part of our autotransfusion program, we have recently had the possibility to introduce plasma predeposit by means of productive plasmapheresis in patients undergoing major orthopaedic surgery, in which bleeding more than 50-60% of circulating blood mass was expected and so a greater quantity of plasma compared to red blood cells was considered necessary. Red cells and fresh frozen plasma predeposits and perioperative blood recovery was sufficient to cover transfusional needs. In our opinion, plasma predepositing by plasmapheresis is indicated in patients with anaemia, cardiopathy and/or vasculopathy, minute constitution.
Collapse
Affiliation(s)
- A. Bassi
- Immunohematological and Transfusion Unit - Rizzoli Orthopaedic Institute, Bologna - Italy
| | - B. Borghi
- 1st Anaesthesia and Intensive Care Unit IRCCS - Rizzoli Orthopaedic Institute, Bologna - Italy
| | - C. Brillante
- Immunohematological and Transfusion Unit - Rizzoli Orthopaedic Institute, Bologna - Italy
| | - R. Mattioli
- 1st Anaesthesia and Intensive Care Unit IRCCS - Rizzoli Orthopaedic Institute, Bologna - Italy
| |
Collapse
|
15
|
Montanari M, Fabbri F, Rondini E, Frassineti GL, Mattioli R, Carloni S, Scarpi E, Zoli W, Amadori D, Cruciani G. Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori 2018; 98:696-701. [DOI: 10.1177/030089161209800604] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Aims and background Non-pegylated liposomal doxorubicin (NPLD) (Myocet) has shown marked in vitro activity in castration-resistant prostate cancer (CRPC) and also in docetaxel-resistant cells, higher than that shown by pegylated liposomal doxorubicin. Its activity would seem to be due to a high intracellular drug concentration and induction of Golgi-dependent apoptosis. On the basis of these results, a clinical study was designed to assess the activity of NPLD and low-dose prednisone in second-line therapy. Methods Fifty-four patients were enrolled and evaluated. Eligibility criteria were histologically confirmed CRPC, PSA >20 ng/mL or measurable lesions according to the RECIST criteria, previous docetaxel-based chemotherapy, and adequate cardiac function. Patients were treated with weekly intravenous NPLD 25 mg/m2 and daily prednisone 10 mg until progression. Results Median patient age was 69 years (range, 52–83) and median baseline PSA concentration was 120 ng/mL (range, 5.35–4350). Sixteen (29.6%) patients had measurable lesions. Objective or PSA responses (>50% reduction) were observed in 8 (14.8%) patients. The median time to progression was 2.8 months and the median overall survival was 11.3 months. Toxicity was generally mild (grade 1–2) and infrequent, with grade 3–4 neutropenia in 12.9% of cases. Grade 3 nonhematological toxicities included nausea in 2 patients (3.7%) and fatigue and stomatitis in 1 case (1.9%). No drug-related serious adverse events were reported. Conclusions Weekly administration of NPLD is a well tolerated treatment with proven albeit limited activity.
Collapse
Affiliation(s)
| | - Francesco Fabbri
- Biosciences Laboratory, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC)
| | | | - Giovanni Luca Frassineti
- Department of Medical Oncology, IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC)
| | | | - Silvia Carloni
- Biosciences Laboratory, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC)
| | - Emanuela Scarpi
- Department of Medical Oncology, IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC)
| | - Wainer Zoli
- Biosciences Laboratory, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC)
| | - Dino Amadori
- Department of Medical Oncology, IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC)
| | | |
Collapse
|
16
|
Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A. Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review. Tumori 2018; 97:690-2. [DOI: 10.1177/030089161109700602] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Mario Airoldi
- SC Oncologia Medica 2, Presidio Ospedaliero San Giovanni Antica Sede, Turin
| | - Dino Amadori
- UO Oncologia Medica, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC)
| | - Sandro Barni
- UO Oncologia Medica, Azienda Ospedaliera Treviglio Caravaggio, Treviglio (BG)
| | - Saverio Cinieri
- UO Oncologia Medica & Breast Unit, Presidio Ospedaliero Senatore Antonio Perrino, Brindisi, Medical Oncology Dept, European Institute of Oncology, (IRCSS) Milan
| | - Sabino De Placido
- Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università Federico II, Facoltà di Medicina e Chirurgia, Naples
| | - Angelo Di Leo
- UO Oncologia Medica “Sandro Pitigliani”, Ospedale Misericordia e Dolce, Azienda USL 4, Prato
| | | | - Stefano Iacobelli
- UO Oncologia Medica, Policlinico Universitario SS. Annunziata UO, Chieti
| | - Maria Teresa Ionta
- SC Oncologia Medica II, Azienda Ospedaliero-Universitaria di Cagliari, Monserrato (CA)
| | | | - Marzia Lotrionte
- Unità per lo Scompenso Cardiaco e la Riabilitazione Cardiologia, Dept Medicina Cardiovascolare, Università Cattolica del Sacro Cuore, Complesso Integrato Columbus, Rome
| | | | | | | | - Paolo Pronzato
- Oncologia Medica A, Istituto Nazionale per la Ricerca sul Cancro, Genoa
| | | | - Carlo Alberto Tondini
- UO Oncologia Medica, Gruppo Multidisciplinare di Senologia, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo
| | - Andrea Veronesi
- UO Oncologia Medica C, Centro di Riferimento Oncologico, Aviano (PN), Italy
| |
Collapse
|
17
|
Tomasello G, Valeri N, Ghidini M, Smyth EC, Liguigli W, Toppo L, Mattioli R, Curti A, Hahne JC, Negri FM, Panni S, Ratti M, Lazzarelli S, Gerevini F, Colombi C, Panni A, Rovatti M, Treccani L, Martinotti M, Passalacqua R. First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. Oncotarget 2017; 8:111795-111806. [PMID: 29340092 PMCID: PMC5762360 DOI: 10.18632/oncotarget.22909] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Accepted: 11/15/2017] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Survival for patients with advanced gastroesophageal cancer (AGC) using standard treatment regimens is poor. EGFR overexpression is common in AGC and associated with poor prognosis. We hypothesized that increasing the dose intensity of chemotherapy and adding panitumumab could improve efficacy. METHODS HER2 negative, PS 0-1 patients, received up to 4 cycles of panitumumab 6 mg/kg d 1, docetaxel 60 mg/m2 d 1, cisplatin 50 mg/m2 d 1, l-folinic acid 100 mg/m2 d 1-2, followed by 5-FU 400 mg/m2 bolus d 1-2, and then 600 mg/m2 as a 22 h c.i. on d 1-2, q15 d, plus pegfilgrastim 6 mg on d 3. Patients with disease control after 4 cycles received panitumumab until progression. RESULTS From 05/2010 to 01/2014, 52 patients (75% male; median age 64.5 y; metastatic 90%, locally advanced 10%; 96% adenocarcinoma; 25% GEJ) were recruited. Three CR, 29 PR, 10 SD and 8 PD were observed, for an ORR by ITT (primary endpoint) of 62% (95% CI, 48%-75%) and a DCR of 81%. Median TTP was 4.9 months (95% CI, 4.2-7.0) and mOS 10 months (95% CI, 8.2- 13.5). Most frequent G3-4 toxicities: leucopenia (29%), asthenia (27%), skin rash (25%), neutropenia (19%), anorexia (17%), febrile neutropenia (13%), and diarrhea (15%). EGFR expression tested both with dd-PCR and FISH was not associated with any significant clinical benefit from treatment. CONCLUSIONS Dose-dense DCF plus panitumumab is an active regimen. However, the toxicity profile of this limits further development. Further research on predictive biomarkers for treatment efficacy in AGC is required.Clinical trial information: 2009-016962-10.
Collapse
Affiliation(s)
| | - Nicola Valeri
- Division of Molecular Pathology, The Institute for Cancer Research, Sutton, London, UK
- Department of Medicine, The Royal Marsden Hospital, Sutton, London, UK
| | | | | | - Wanda Liguigli
- Oncology Division, ASST Ospedale di Cremona, Cremona, Italy
| | - Laura Toppo
- Oncology Division, ASST Ospedale di Cremona, Cremona, Italy
| | | | | | - Jens C. Hahne
- Division of Molecular Pathology, The Institute for Cancer Research, Sutton, London, UK
| | | | - Stefano Panni
- Oncology Division, ASST Ospedale di Cremona, Cremona, Italy
| | | | | | | | - Chiara Colombi
- Oncology Division, ASST Ospedale di Cremona, Cremona, Italy
| | - Andrea Panni
- Pathology Division, ASST Ospedale di Cremona, Cremona, Italy
| | | | | | | | | |
Collapse
|
18
|
Fernandes CEM, Serafim KR, Gianlorenco ACL, Mattioli R. Intra-vermis H4 receptor agonist impairs performance in anxiety- and fear-mediated models. Brain Res Bull 2017; 135:179-184. [PMID: 29097243 DOI: 10.1016/j.brainresbull.2017.10.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 10/26/2017] [Accepted: 10/27/2017] [Indexed: 11/26/2022]
Abstract
The neural histaminergic system modulates cognitive performance in various animal models. However, little is known about the effects of the H4 histaminergic receptor in the central nervous system. The purpose of this study was to investigate the effect of histaminergic H4 agonist VUF-8430 microinjection into the cerebellar vermis on the consolidation of emotional memory in mice subjected to the elevated plus maze (EPM) and inhibitory avoidance task (IAT). All experiments were performed on two consecutive days: exposure (T1 and D1) and 24h after, which we called re-exposure (T2 and D2). The animals received saline (SAL) or VUF (0.15 nmol; 0.49 nmol; 1.48 nmol/0.1μl) administered post-exposure. Experiment 1 was conducted in the EPM, and the animals were free to explore the maze for 5min. In T1, immediately after exposure, the pharmacological treatment was given; in T2, there was only re-exposure to the EPM. Experiment 2 involved the IAT, and the pharmacological treatment was provided post-D1; in D2, the animals were only re-exposed to the IAT. In Experiment 1, increased open arm exploration (% open arm entries and% open arms time) for 0.49 and 1.48nmol of VUF were recorded in T2 compared to T1. In Experiment 2, a significant decrease in consolidation latency was recorded for the group that received 1.48nmol of VUF compared to the SAL group in D2. These results indicate that a 1.48nmol VUF microinjection into the cerebellar vermis impaired performance in both models, even though one model was anxiety-mediated (EPM) and the other was fear-mediated (IAT).
Collapse
Affiliation(s)
- C E M Fernandes
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, Rod. Washington Luis, Km 235, 13565-905 Sao Carlos, Brazil.
| | - K R Serafim
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, Rod. Washington Luis, Km 235, 13565-905 Sao Carlos, Brazil.
| | - A C L Gianlorenco
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, Rod. Washington Luis, Km 235, 13565-905 Sao Carlos, Brazil.
| | - R Mattioli
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, Rod. Washington Luis, Km 235, 13565-905 Sao Carlos, Brazil.
| |
Collapse
|
19
|
Catalano V, Bergamo F, Cremolini C, Vincenzi B, Negri F, Graziano F, Giordani P, Alessandroni P, Intini R, Rumanò L, Rossini D, Borelli B, Santini D, Sarti D, Rocchi M, Lonardi S, Falcone A, Zagonel V, Mattioli R. Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J, Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Keil F, Samonigg H, Zabernigg A, Schmid F, Steger G, Steinacher R, Andel J, Jagdt B, Lang A, Fridrik M, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, D'Haens G, Demolin G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, Kalantari HR, Delaunoit T, Goeminne JC, Peeters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlisz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaille C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Aparicio T, Perrier H, Stremsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Coriat R, Denis B, Geoffroy P, Piot G, Becouarn Y, Bordes G, Deplanque G, Dupuis O, Fruge F, Guimbaud R, Lecomte T, Lledo G, Sobhani I, Asnacios A, Azzedine A, Desauw C, Galais MP, Gargot D, Lam YH, Abakar-Mahamat A, Berdah JF, Catteau S, Clavero-Fabri MC, Codoul JF, Legoux JL, Goldfain D, Guichard P, Verge DP, Provencal J, Vedrenne B, Brezault-Bonnet C, Cleau D, Desir JP, Fallik D, Garcia B, Gaspard MH, Genet D, Hartwig J, Krummel Y, Budnik TM, Palascak-Juif V, Randrianarivelo H, Rinaldi Y, Aleba A, Darut-Jouve A, de Gramont A, Hamon H, Wendehenne F, Matzdorff A, Stahl MK, Schepp W, Burk M, Mueller L, Folprecht G, Geissler M, Mantovani-Loeffler L, Hoehler T, Asperger W, Kroening H, von Weikersthal LF, Fuxius S, Groschek M, Meiler J, Trarbach T, Rauh J, Ziegenhagen N, Kretzschmar A, Graeven U, Nusch A, von Wichert G, Hofheinz RD, Kleber G, Schmidt KH, Vehling-Kaiser U, Baum C, Schuette J, Haag GM, Holtkamp W, Potenberg J, Reiber T, Schliesser G, Schmoll HJ, Schneider-Kappus W, Abenhardt W, Denzlinger C, Henning J, Marxsen B, Derigs HG, Lambertz H, Becker-Boost I, Caca K, Constantin C, Decker T, Eschenburg H, Gabius S, Hebart H, Hoffmeister A, Horst HA, Kremers S, Leithaeuser M, Mueller S, Wagner S, Daum S, Schlegel F, Stauch M, Heinemann V, Maiello E, Latini L, Zaniboni A, Amadori D, Aprile G, Barni S, Mattioli R, Martoni A, Passalacqua R, Nicolini M, Pasquini E, Rabbi C, Aitini E, Ravaioli A, Barone C, Biasco G, Tamberi S, Gambi A, Verusio C, Marzola M, Lelli G, Boni C, Cascinu S, Bidoli P, Vaghi M, Cruciani G, Di Costanzo F, Sobrero A, Mini E, Petrioli R, Aglietta M, Alabiso O, Capuzzo F, Falcone A, Corsi DC, Labianca R, Salvagni S, Chiara S, Ciuffreda L, Ferraù F, Giuliani F, Lonardi S, Gebbia N, Mantovani G, Sanches E, Mellidez JC, Santos P, Freire J, Sarmento C, Costa L, Pinto AM, Barroso S, Santo JE, Guedes F, Monteiro A, Sa A, Furtado I, Salazar R, Aguilar EA, Herrero FR, Tabernero J, Valera JS, Ayerbes MV, Batlle JF, Gil S, Esteve AA, Garcia-Giron C, Vivanco GL, Salvia AS, Orduña VA, Garcia RV, Gallego J, Sureda BM, Remon J, Safont Aguilera MJ, Nogueras LC, Merino BQ, Castro CG, de Prado PM, Pericay CP, Figueiras MC, Jordan IG, Gome Reina MJ, Garcia ALL, Garcia-Ramos AA, Cervantes A, Martos CF, Gaspar EM, Montero IC, Emperador PE, Carbonero AL, Castillo MG, Garcia TG, Lopez JG, Flores EG, Morales MG, Muñoz ML, Martín AL, Maurel J, Camara JC, Garcia RD, Salgado M, Busquier IH, Ruiz TC, Muñoa AL, Aliguer MN, de Taranco AVO, Ureña MM, Gaspa FL, Ponce JJ, Roig CB, Jimenez PV, Brotons AG, Rodriguez SA, Martinez JA, Ruiz LC, Ruiz MC, Bridgewater J, Glynne-Jones R, Tahir S, Hickish T, Cassidy J, Samuel L. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. Eur J Cancer 2017. [DOI: 10.1016/j.ejca.2017.04.025] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
21
|
Fernandes CEM, Serafim KR, Gianlorenço ACL, Mattioli R. Cholinergic agonist reverses H1-induced memory deficit in mice. Prog Neuropsychopharmacol Biol Psychiatry 2017; 72:16-22. [PMID: 27528108 DOI: 10.1016/j.pnpbp.2016.08.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Revised: 07/28/2016] [Accepted: 08/11/2016] [Indexed: 01/15/2023]
Abstract
This study investigated the effects of bilateral intraamygdalar microinjections of PNU-282987, a nicotinic cholinergic agonist, on anxiety and the reversal of amnesia induced by chlorpheniramine (CPA), an H1 histaminergic antagonist, in mice subjected to the elevated plusmaze (EPM). Two experiments were performed with seventy-nine adult male Swiss mice. The isolated microinjections of PNU-282987 did not produce effects on emotional memory; however, the combined microinjections of PNU-282987 and CPA were able to reverse the deficit in memory induced by CPA (ANOVA, p<0.05). Taken together, these results suggest that intraamygdalar injections of PNU-282987 did not induce effects on anxiety and emotional memory per se; however, concurrent microinjections of PNU-282987 and CPA-reverse amnesia induced-CPA which is suggestive of an interaction between the histaminergic and cholinergic systems in the modulation of emotion memory acquisition in mice.
Collapse
Affiliation(s)
- C E M Fernandes
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, Rod. Washington Luis, Km 235, 13565-905 Sao Carlos, Brazil.
| | - K R Serafim
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, Rod. Washington Luis, Km 235, 13565-905 Sao Carlos, Brazil.
| | - A C L Gianlorenço
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, Rod. Washington Luis, Km 235, 13565-905 Sao Carlos, Brazil.
| | - R Mattioli
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, Rod. Washington Luis, Km 235, 13565-905 Sao Carlos, Brazil.
| |
Collapse
|
22
|
Mercadante S, Marchetti P, Cuomo A, Caraceni A, Mediati RD, Mammucari M, Natoli S, Lazzari M, Dauri M, Airoldi M, Azzarello G, Bandera M, Blasi L, Cartenì G, Chiurazzi B, Costanzo BVP, Degiovanni D, Fusco F, Guardamagna V, Iaffaioli V, Liguori S, Lorusso V, Mameli S, Mattioli R, Mazzei T, Melotti RM, Menardo V, Miotti D, Moroso S, De Santis S, Orsetti R, Papa A, Ricci S, Sabato AF, Scelzi E, Sofia M, Tonini G, Aielli F, Valle A. Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). Adv Ther 2017; 34:120-135. [PMID: 27873235 PMCID: PMC5216057 DOI: 10.1007/s12325-016-0440-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Indexed: 11/29/2022]
Abstract
Introduction An ongoing national multicenter survey [Italian Oncologic Pain multiSetting Multicentric Survey (IOPS-MS)] is evaluating the characteristics of breakthrough cancer pain (BTP) in different clinical settings. Preliminary data from the first 1500 cancer patients with BTP enrolled in this study are presented here. Methods Thirty-two clinical centers are involved in the survey. A diagnosis of BTP was performed by a standard algorithm. Epidemiological data, Karnofsky index, stage of disease, presence and sites of metastases, ongoing oncologic treatment, and characteristics of background pain and BTP and their treatments were recorded. Background pain and BTP intensity were measured. Patients were also questioned about BTP predictability, BTP onset (≤10 or >10 min), BTP duration, background and BTP medications and their doses, time to meaningful pain relief after BTP medication, and satisfaction with BTP medication. The occurrence of adverse reactions was also assessed, as well as mucosal toxicity. Results Background pain was well controlled with opioid treatment (numerical rating scale 3.0 ± 1.1). Patients reported 2.5 ± 1.6 BTP episodes/day with a mean intensity of 7.5 ± 1.4 and duration of 43 ± 40 min; 977 patients (65.1%) reported non-predictable BTP, and 1076 patients (71.7%) reported a rapid onset of BTP (≤10 min). Higher patient satisfaction was reported by patients treated with fast onset opioids. Conclusions These preliminary data underline that the standard algorithm used is a valid tool for a proper diagnosis of BTP in cancer patients. Moreover, rapid relief of pain is crucial for patients’ satisfaction. The final IOPS-MS data are necessary to understand relationships between BTP characteristics and other clinical variables in oncologic patients. Funding Molteni Farmaceutici, Italy.
Collapse
Affiliation(s)
- Sebastiano Mercadante
- Anesthesia and Intensive Care and Pain Relief and Supportive Care, La Maddalena Cancer Center, Via San Lorenzo 312, 90146, Palermo, Italy.
| | - Paolo Marchetti
- Molecular and Clinical Medicine, Medical Oncology, La Sapienza University of Rome, Rome, Italy
| | - Arturo Cuomo
- Anesthesiology, Resuscitation, and Pain Therapy Department, National Cancer Institute, IRCCS Foundation Pascale, Naples, Italy
| | - Augusto Caraceni
- Palliative Care, Pain Therapy and Rehabilitation, National Cancer Institute IRCCS Foundation, Milan, Italy
| | | | | | - Silvia Natoli
- Department of Clinical Science and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
- Department of Emergency, Admission and Critical Area, Policlinic of Tor Vergata, Rome, Italy
| | - Marzia Lazzari
- Department of Clinical Science and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
- Department of Emergency, Admission and Critical Area, Policlinic of Tor Vergata, Rome, Italy
| | - Mario Dauri
- Department of Clinical Science and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
- Department of Emergency, Admission and Critical Area, Policlinic of Tor Vergata, Rome, Italy
| | - Mario Airoldi
- 2nd Medical Oncology Division, Città della Salute e della Scienza Hospital of Turin, Turin, Italy
| | - Giuseppe Azzarello
- Medical Specialties Department, Oncology and Oncologic Hematology, ASL 13 Mirano, Venice, Italy
| | - Mauro Bandera
- Medical Oncology Unit, Ospedale di Circolo e Fondazione Macchi Hospital, Varese, Italy
| | - Livio Blasi
- Medical Oncology Unit, ARNAS Ospedale Civico, Di Cristina, Benfratelli, Palermo, Italy
| | | | | | | | | | - Flavio Fusco
- Palliative Care Unit, Department of Primary and Community Care, ASL3 Genovese, Genoa, Italy
| | - Vittorio Guardamagna
- Palliative Care and Pain Therapy Unit, European Oncology Institute IRCCS, Milan, Italy
| | - Vincenzo Iaffaioli
- Abdominal Medical Oncology, National Cancer Institute, IRCCS Foundation Pascale, Naples, Italy
| | - Simeone Liguori
- Palliative Care and Pain Therapy Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - Vito Lorusso
- Medical Oncology Unit, National Cancer Research Centre "Giovanni Paolo II", Bari, Italy
| | - Sergio Mameli
- Pain Therapy Unit, "A. Businco" Hospital, ASL 8, Cagliari, Italy
| | | | - Teresita Mazzei
- Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
| | - Rita Maria Melotti
- Department of Medicine and Surgery Sciences, University of Bologna, Bologna, Italy
| | | | - Danilo Miotti
- Palliative Care Unit, Salvatore Maugeri-IRCCS Foundation, Pavia, Italy
| | - Stefano Moroso
- Medical Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
| | - Stefano De Santis
- Palliative Care and Oncologic Pain Service, S. Camillo-Forlanini Hospital, Rome, Italy
| | - Remo Orsetti
- Pain Medicine Unit, S. Camillo-Forlanini Hospital, Rome, Italy
| | - Alfonso Papa
- Pain Relief, A.O. Dei Colli, Monaldi Hospital, Naples, Italy
| | - Sergio Ricci
- Division of Medical Oncology, Department of Oncology, S. Chiara University Hospital, Pisa, Italy
| | - Alessandro Fabrizio Sabato
- Department of Clinical Science and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
- Department of Emergency, Admission and Critical Area, Policlinic of Tor Vergata, Rome, Italy
| | - Elvira Scelzi
- Medical Oncology, Castelfranco Veneto Hospital, Treviso, Italy
| | - Michele Sofia
- Department of Palliative Care with Hospice and Pain Therapy Unit, "G.Salvini" Hospital, Garbagnate Milanese, Milan, Italy
| | - Giuseppe Tonini
- Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy
| | - Federica Aielli
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | | |
Collapse
|
23
|
Canto-de-Souza L, Mattioli R. The consolidation of inhibitory avoidance memory in mice depends on the intensity of the aversive stimulus: The involvement of the amygdala, dorsal hippocampus and medial prefrontal cortex. Neurobiol Learn Mem 2016; 130:44-51. [PMID: 26851130 DOI: 10.1016/j.nlm.2016.01.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Revised: 01/13/2016] [Accepted: 01/26/2016] [Indexed: 01/10/2023]
Abstract
Several studies using inhibitory avoidance models have demonstrated the importance of limbic structures, such as the amygdala, dorsal hippocampus and medial prefrontal cortex, in the consolidation of emotional memory. However, we aimed to investigate the role of the amygdala (AMG), dorsal hippocampus (DH) and medial prefrontal cortex (mPFC) of mice in the consolidation of step-down inhibitory avoidance and whether this avoidance would be conditioned relative to the intensity of the aversive stimulus. To test this, we bilaterally infused anisomycin (ANI-40μg/μl, a protein synthesis inhibitor) into one of these three brain areas in mice. These mice were then exposed to one of two different intensities (moderate: 0.5mA or intense: 1.5mA) in a step-down inhibitory avoidance task. We found that consolidation of both of the aversive experiences was mPFC dependent, while the AMG and DH were only required for the consolidation of the intense experience. We suggest that in moderately aversive situations, which do not represent a severe physical risk to the individual, the consolidation of aversive experiences does not depend on protein synthesis in the AMG or the DH, but only the mPFC. However, for intense aversive stimuli all three of these limbic structures are essential for the consolidation of the experience.
Collapse
Affiliation(s)
- L Canto-de-Souza
- Laboratório de Neurociências, Departamento de Fisioterapia, Centro de Ciências Biológicas e Saúde, Universidade Federal de São Carlos, Rod. Washington Luis, Km 235, 13565-905 São Carlos, Brazil; Programa de Pós-Graduação em Psicobiologia, Universidade de São Paulo, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Departamento de Psicologia, Avenida Bandeirantes, 3900, Monte Alegre, CEP 14040-901, Ribeirão Preto, SP, Brazil; INeC, Instituto de Neurociências e Comportamento, Avenida Bandeirantes, 3900, CEP 14040-901, Monte Alegre, Ribeirão Preto, SP, Brazil.
| | - R Mattioli
- Laboratório de Neurociências, Departamento de Fisioterapia, Centro de Ciências Biológicas e Saúde, Universidade Federal de São Carlos, Rod. Washington Luis, Km 235, 13565-905 São Carlos, Brazil; Programa de Pós-Graduação em Psicobiologia, Universidade de São Paulo, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Departamento de Psicologia, Avenida Bandeirantes, 3900, Monte Alegre, CEP 14040-901, Ribeirão Preto, SP, Brazil.
| |
Collapse
|
24
|
Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D'Angelo A, Spizzo G, Bortolus R, Donini M, Lo Re G, Massari F, Vicario G, Zucali PA, Alesini D, Bonetti A, Mucciarini C, Nicodemo M, Berruti A, Fratino L, Lodde M, Messina C, Perin A, Santini D, Sava T, Tucci M, Basso U, Maines F, Burgio LS, Galligioni E. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. Future Oncol 2016; 12:493-502. [PMID: 26776493 DOI: 10.2217/fon.15.302] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIM To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer. PATIENTS & METHODS The multicenter retrospective study was based on a review of the pre- and post-DOC clinical history, DOC treatment and outcomes. RESULTS We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3-4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival. CONCLUSION The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.
Collapse
Affiliation(s)
- Antonello Veccia
- Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38100 Trento, Italy
| | - Orazio Caffo
- Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38100 Trento, Italy
| | - Ugo De Giorgi
- Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014 Meldola, Italy
| | - Giuseppe Di Lorenzo
- Oncologia Urologica, Azienda Ospedaliera Universitaria "Federico II", Via S. Pansini 5, 80131 Napoli, Italy
| | - Cinzia Ortega
- Medical Oncology Department, Institute for Cancer Research & Treatment, Strada Provinciale 142, Km 3.95, 10060 Candiolo, Italy
| | - Florinda Scognamiglio
- Medical Oncology Department, Cardarelli Hospital, Via A. Cardarelli 9, 80131 Napoli, Italy
| | - Michele Aieta
- Medical Oncology Department, Referral Cancer Center of Basilicata - IRCCS, Via Padre Pio, 1, 85028 Rionero in Vulture, Italy
| | - Gaetano Facchini
- Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via Mariano Semmola, 80131 Naples, Italy
| | - Giovanni Mansueto
- Medical Oncology Department, General Hospital, Via Fabi, 03100 Frosinone, Italy
| | - Rodolfo Mattioli
- Medical Oncology Department, Santa Croce Hospital, Viale Vittorio Veneto 2, 61032 Fano, Italy
| | - Giuseppe Procopio
- Oncologia medica genitourinaria - Fondazione Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
| | - Vittorina Zagonel
- Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata 64, 35128 Padua, Italy
| | - Alessandro D'Angelo
- Medical Oncology Department, San Vincenzo Hospital, Via Sirina, 98039 Taormina, Italy
| | - Gilbert Spizzo
- Medical Oncology Department, General Hospital, Via Rossini, 5, 39012 Merano, Italy
| | - Roberto Bortolus
- Radiation Oncology Department, National Cancer Institute, Via Franco Gallini, 2, 33081 Aviano, Italy
| | - Maddalena Donini
- Medical Oncology Department, Istituti Ospitalieri, Viale Concordia 1, 26100 Cremona, Italy
| | - Giovanni Lo Re
- Medical Oncology Department, Santa Maria degli Angeli Hospital, Via Montereale 24, 33170 Pordenone, Italy
| | - Francesco Massari
- Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale A. Scuro 10, 37134 Verona, Italy
| | - Giovanni Vicario
- Medical Oncology Department, San Giacomo Apostolo Hospital, Via dei Carpani 16/Z, 31033 Castelfranco Veneto, Italy
| | - Paolo A Zucali
- Department of Medical Oncology & Haematology, Humanitas Clinical & Research Center, Via Manzoni, 56, 20089 Rozzano, Italy
| | - Daniele Alesini
- Department of Radiological, Oncological & Anatomopathological Sciences, La Sapienza, University of Rome, Piazzale Aldo Moro, 5, 00185 Rome, Italy
| | - Andrea Bonetti
- Medical Oncology Department, Mater Salutis Hospital, Via Gianella, 1, 37045 Legnago, Italy
| | - Claudia Mucciarini
- Medical Oncology Department, Ramazzini Hospital, Via Guido Molinari, 2, 41012 Carpi, Italy
| | - Maurizio Nicodemo
- Medical Oncology Department, Sacro Cuore Don Calabria Hospital, Via don A. Sempreboni, 5, 37024 Negrar, Italy
| | - Alfredo Berruti
- Medical Oncology Department, Spedali Civili Hospital, P.le Spedali Civili, 1, 25123 Brescia, Italy
| | - Lucia Fratino
- Medical Oncology Department, National Cancer Institute, Via Franco Gallini, 2, 33081 Aviano, Italy
| | - Michele Lodde
- Urology Department, General Hospital, Via Böhler 5, 39100 Bolzano, Italy
| | - Caterina Messina
- Medical Oncology Department, Papa Giovanni XXIII Hospital, Piazza OMS 1, 24127 Bergamo, Italy
| | - Alessandra Perin
- Medical Oncology Department, General Hospital, via Garziere n. 42, 36014 Santorso, Italy
| | - Daniele Santini
- Medical Oncology Department, University Campus Bio-Medico, Via Álvaro del Portillo, 00128 Rome, Italy
| | - Teodoro Sava
- Medical Oncology Department, General Hospital, P.le A. Stefani 1, 37126 Verona, Italy
| | - Marcello Tucci
- Medical Oncology Department, University of Torino, San Luigi Hospital, Regione Gonzole, 10, 10043 Orbassano, Italy
| | - Umberto Basso
- Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata 64, 35128 Padua, Italy
| | - Francesca Maines
- Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38100 Trento, Italy
| | - Luca S Burgio
- Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014 Meldola, Italy
| | - Enzo Galligioni
- Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38100 Trento, Italy
| |
Collapse
|
25
|
Merlano M, Vecchio S, Bacigalupo A, Russi E, Denaro N, Ostellino O, Rampino M, Benasso M, Boitano M, Numico G, D'Amico M, Grimaldi A, Blengio F, Licitra L, Pinto C, Aieta M, Bui S, Mattioli R, Bertolini F, Gasparini G, Boni C. The phase III study INTERCEPTOR in locally advanced head and neck cancer (LA-HNC). Preliminary safety report. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv342.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Veccia A, Caffo O, Burgio SL, di Lorenzo G, Ortega C, Scognamiglio F, Mattioli R, Mansueto G, Zustovich F, Aieta M, Facchini G, Procopio G, D'Angelo A, Spizzo G, De Giorgi U, De Placido S, Ruatta F, Galligioni E. Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e16017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Salvatore Luca Burgio
- IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Giuseppe di Lorenzo
- Medical Oncology Unit, Department of Clinical Medicine, Federico II University, Naples, Italy
| | - Cinzia Ortega
- Fondazione del Piemonte per l'Oncologia-Institute for Cancer Research and Treatment, Candiolo (Turin), Italy
| | | | | | | | - Fable Zustovich
- Medical Oncology 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy
| | - Michele Aieta
- IRCCS CROB Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Gaetano Facchini
- National Cancer Institute at the National Institutes of Health, Naples, Italy
| | - Giuseppe Procopio
- Oncology Unit I, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
| | | | | | - Ugo De Giorgi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS, Meldola, Italy
| | | | - Fiorella Ruatta
- Medical Oncology, Fondazione del Piemonte per l'Oncologia-Institute for Cancer Research and Treatment, Candiolo, Italy
| | | | | |
Collapse
|
27
|
Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, Zabernigg A, Schmid F, Steger G, Steinacher R, Andel J, Lang A, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, Van Laethem JL, Van Cutsem E, D'Haens G, Demolin G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, RezaieKalantari H, Delaunoit T, Goeminne JC, Peeters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlisz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Ychou M, Zawadi A, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche, Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaille C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Aparicio T, Perrier H, Stremsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Coriat R, Denis B, Geoffroy P, Piot G, Becouarn Y, Bordes G, Deplanque G, Dupuis O, Fruge F, Guimbaud R, Lecomte T, Lledo G, Sobhani I, Asnacios A, Azzedine A, Desauw C, Galais MP, Gargot D, Lam YH, Abakar-Mahamat A, Berdah JF, Catteau S, Clavero-Fabri MC, Codoul JF, Legoux JL, Goldfain D, Guichard P, Verge DP, Provencal J, Vedrenne B, Brezault-Bonnet C, Cleau D, Desir JP, Fallik D, Garcia B, Gaspard MH, Genet D, Hartwig J, Krummel Y, MatysiakBudnik T, Palascak-Juif V, Randrianarivelo H, Rinaldi Y, Aleba A, Darut-Jouve A, de Gramont A, Hamon H, Wendehenne F, Matzdorff A, Stahl MK, Schepp W, Burk M, Mueller L, Folprecht G, Geissler M, Mantovani-Loeffler L, Hoehler T, Asperger W, Kroening H, von Weikersthal LF, Fuxius S, Groschek M, Meiler J, Trarbach T, Rauh J, Ziegenhagen N, Kretzschmar A, Graeven U, Nusch A, von Wichert G, Hofheinz RD, Kleber G, Schmidt KH, Vehling-Kaiser U, Baum C, Schuette J, Haag GM, Holtkamp W, Potenberg J, Reiber T, Schliesser G, Schmoll HJ, Schneider-Kappus W, Abenhardt W, Denzlinger C, Henning J, Marxsen B, GuenterDerigs H, Lambertz H, Becker-Boost I, Caca K, Constantin C, Decker T, Eschenburg H, Gabius S, Hebart H, Hoffmeister A, Horst HA, Kremers S, Leithaeuser M, Mueller S, Wagner S, Daum S, Schlegel F, Stauch M, Heinemann V, Labianca R, Colucci G, Amadori D, Mini E, Falcone A, Boni C, Maiello E, Latini L, Zaniboni A, Amadori D, Aprile G, Barni S, Mattioli R, Martoni A, Passalacqua R, Nicolini M, Pasquini E, Rabbi C, Aitini E, Ravaioli A, Barone C, Biasco G, Tamberi S, Gambi A, Verusio C, Marzola M, Lelli G, Boni C, Cascinu S, Bidoli P, Vaghi M, Cruciani G, Di Costanzo F, Sobrero A, Mini E, Petrioli R, Aglietta M, Alabiso O, Capuzzo F, Falcone A, Corsi DC, Labianca R, Salvagni S, Chiara S, Ferraù F, Giuliani F, Lonardi S, Gebbia N, Mantovani G, Sanches E, Sanches E, Mellidez JC, Santos P, Freire J, Sarmento C, Costa L, Pinto AM, Barroso S, Santo JE, Guedes F, Monteiro A, Sa A, Furtado I, Tabernero J, Salazar R, Aguilar EA, Herrero FR, Tabernero J, Valera JS, ValladaresAyerbes M, FeliuBatlle J, Gil S, Garcia-Giron C, Vivanco GL, Salvia AS, Orduña VA, Garcia RV, Gallego J, Sureda BM, Remon J, Safont Aguilera MJ, CireraNogueras L, Merino B, Castro CG, de Prado PM, PijaumePericay C, ConstenlaFigueiras M, Jordan I, GomeReina MJ, Garcia ALL, Garcia-Ramos AA, Cervantes A, Martos CF, MarcuelloGaspar E, Montero IC, Emperador PE, Carbonero AL, Castillo MG, Garcia TG, Lopez JG, Flores EG, GuillotMorales M, LlanosMuñoz M, Martín AL, Maurel J, Camara JC, Garcia RD, Salgado M, HernandezBusquier I, Ruiz TC, LacastaMuñoa A, Aliguer M, Ortiz de Taranco AV, Ureña MM, Gaspa FL, Ponce JJ, Roig CB, Jimenez PV, GalanBrotons A, AlbiolRodriguez S, Martinez JA, Ruiz LC, CentellesRuiz M, Bridgewater J, Glynne-Jones R, Tahir S, Hickish T, Cassidy J, Samuel L. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol 2015; 26:822-825. [DOI: 10.1093/annonc/mdv070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Tomasello G, Liguigli W, Toppo L, Mattioli R, Negri F, Curti A, Ratti M, Poli R, Lazzarelli S, Gerevini F, Colombi C, Martinotti M, Rovatti M, Olivetti L, Passalacqua R. First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5- fluorouracil (DCF) plus panitumumab (P) in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction (GEJ): A phase II multicenter trial. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.3_suppl.146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
146 Background: Gastric cancer is a highly aggressive disease. No established standard first-line regimens are currently available. Aim of this study is to evaluate efficacy of dose-dense chemotherapy with DCF combined with P in patients (pts) with locally advanced or metastatic cancer of the stomach or GEJ. Methods: HER2 negative, ECOG PS 0-1, not previously treated pts, received up to 4 cycles of therapy with Panitumumab 6 mg/kg d 1, Docetaxel 60 mg/m2 d 1, Cisplatin 50 mg/m2 d 1, L-Folinic acid 100 mg/m2 d 1 and 2, followed by 5-FU 400 mg/m2 bolus d 1 and 2, and then 600 mg/m2 as a 22 h c.i. on d 1 and 2, every 2 weeks, plus Pegfilgrastim 6 mg on d 3. Pts aged ≥ 65 years were treated with the same chemotherapy schedule with a dose reduction by 30%. Pts with disease control after 4 cycles, received P until progression. Results: From 05/2010 to 01/2014, 52 consecutive pts were enrolled (75% M, 25% F; median age: 64.5 y, range: 42-75; metastatic 90%, locally advanced inoperable 10%; 96% adenocarcinoma; 13 pts with GEJ cancer). Primary end point was overall response rate (ORR). At 31 Aug 2014 cut-off date, 1 pt is still on treatment, 2 lost at f-up, 11 alive and 39 dead. 50 pts evaluable for response and all for toxicity. A median of 4 cycles (range 0-6) was administered. 3 CR, 29 PR, 10 SD and 8 PD were observed, for an ORR (by ITT) of 62% (95% CI, 48%-75) and a DCR of 81%. 26 pts entered the maintenance phase with only P and received a median 7.3 cycles (range 1-46). Median TTP was 4.8 months (95% CI, 4.1-6.9) and median OS was 9.4 months (95% CI, 7.4- 11.6). Most frequent grade 3-4 toxicities were: leucopenia (29%), neutropenia (19%), febrile neutropenia (13%), anemia (10%), asthenia (27%), mucosytis (13%), anorexia (17%), nausea/vomiting (12%), diarrhea (15%), ipokalemia (12%), and skin rash (25%). Two toxic deaths were registered (pulmonary aspergyllosis due to febrile neutropenia and gastric hemorrhage). Conclusions: Dose-dense chemotherapy combined with P is a very active regimen in gastric cancer. Due to a not negligible toxicity profile, it may represent a treatment option in neoadjuvant setting. Clinical trial information: 2009-016962-10.
Collapse
Affiliation(s)
| | | | - Laura Toppo
- Istituti Ospitalieri di Cremona, Cremona, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Gianlorenço ACL, Riboldi AM, Silva-Marques B, Mattioli R. Cerebellar vermis H₂ receptors mediate fear memory consolidation in mice. Neurosci Lett 2014; 587:57-61. [PMID: 25524412 DOI: 10.1016/j.neulet.2014.12.017] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2014] [Revised: 12/02/2014] [Accepted: 12/11/2014] [Indexed: 01/17/2023]
Abstract
Histaminergic fibers are present in the molecular and granular layers of the cerebellum and have a high density in the vermis and flocullus. Evidence supports that the cerebellar histaminergic system is involved in memory consolidation. Our recent study showed that histamine injections facilitate the retention of an inhibitory avoidance task, which was abolished by pretreatment with an H2 receptor antagonist. In the present study, we investigated the effects of intracerebellar post training injections of H1 and H2 receptor antagonists as well as the selective H2 receptor agonist on fear memory consolidation. The cerebellar vermi of male mice were implanted with guide cannulae, and after three days of recovery, the inhibitory avoidance test was performed. Immediately after a training session, animals received a microinjection of the following histaminergic drugs: experiment 1, saline or chlorpheniramine (0.016, 0.052 or 0.16 nmol); experiment 2, saline or ranitidine (0.57, 2.85 or 5.07 nmol); and experiment 3, saline or dimaprit (1, 2 or 4 nmol). Twenty-four hours later, a retention test was performed. The data were analyzed using one-way analysis of variance (ANOVA) and Duncan's tests. Animals microinjected with chlorpheniramine did not show any behavioral effects at the doses that we used. Intra-cerebellar injection of the H2 receptor antagonist ranitidine inhibited, while the selective H2 receptor agonist dimaprit facilitated, memory consolidation, suggesting that H2 receptors mediate memory consolidation in the inhibitory avoidance task in mice.
Collapse
Affiliation(s)
- A C L Gianlorenço
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, 13565-905, Sao Carlos, Brazil.
| | - A M Riboldi
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, 13565-905, Sao Carlos, Brazil.
| | - B Silva-Marques
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, 13565-905, Sao Carlos, Brazil.
| | - R Mattioli
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, 13565-905, Sao Carlos, Brazil.
| |
Collapse
|
30
|
Canto-de-Souza L, Garção DC, Romaguera F, Mattioli R. Dorsal hippocampal microinjection of chlorpheniramine reverses the anxiolytic-like effects of l-histidine and impairs emotional memory in mice. Neurosci Lett 2014; 587:11-6. [PMID: 25524405 DOI: 10.1016/j.neulet.2014.12.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2014] [Revised: 11/27/2014] [Accepted: 12/11/2014] [Indexed: 10/24/2022]
Abstract
Several findings have pointed to the role of histaminergic neurotransmission in the modulation of anxiety-like behaviors and emotional memory. The elevated plus-maze (EPM) test has been widely used to investigate the process of anxiety and also has been used to investigate the process of learning and memory. Visual cues are relevant to the formation of spatial maps, and as the hippocampus is involved in this task, experiment 1 explored this issue. Experiment 2 investigated the effects of intraperitoneal (i.p.) injections of l-histidine (LH, a precursor of histamine) and of intra-dorsal hippocampus (intra-DH) injections of chlorpheniramine (CPA, an H1 receptor antagonist) on anxiety and emotional memory in mice re-exposed to the EPM. Mice received saline (SAL) or LH i.p. and SAL or CPA (0.016, 0.052, and 0.16 nmol/0.1 μl) intra-DH prior to Trial 1 (T1) and Trial 2 (T2). No significant changes were observed in the number of enclosed-arm entries (EAE) in T1, an EPM index of general exploratory activity. LH had an anxiolytic-like effect that was reversed by intra-DH injections of CPA. T2 versus T1 analysis revealed that only the lower dose of CPA resulted in impaired emotional memory. Combined injections of LH and CPA revealed that higher doses of CPA impair emotional memory. Taken together, these results suggest that LH and H1 receptors present in the dorsal hippocampus are involved in anxiety-related behaviors and emotional memory in mice submitted to EPM.
Collapse
Affiliation(s)
- L Canto-de-Souza
- Laboratório de Neurociências, Universidade Federal de São Carlos, Brazil; Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900, 14040-901, Ribeirão Preto, Brazil.
| | - D C Garção
- Universidade Tiradentes, Rua Lagarto, 264, 49010-390 Aracaju, Brazil.
| | - F Romaguera
- Universidade do Estado de Santa Catarina, Rua Pascoal Simone, 358, 88080-350 Florianópolis, Brazil.
| | - R Mattioli
- Laboratório de Neurociências, Universidade Federal de São Carlos, Brazil.
| |
Collapse
|
31
|
Donini M, Buti S, Lazzarelli S, Bozzetti R, Rivoltini L, Camisaschi C, Castelli C, Bearz A, Simonelli C, Lo Re G, Mattioli R, Caminiti C, Passalacqua R. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). Target Oncol 2014; 10:277-86. [PMID: 25230695 DOI: 10.1007/s11523-014-0337-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2014] [Accepted: 08/29/2014] [Indexed: 02/07/2023]
Abstract
The aim of this study was to explore the efficacy and toxicities of a combined regimen of bevacizumab plus immunotherapy and chemotherapy (BIC) and the circulating T regulatory cells (Treg) in metastatic renal cell cancer (mRCC). Nephrectomized mRCC patients were enrolled into a multicenter single-arm dose-finding study with five escalated dose levels of chemotherapy with intravenous gemcitabine and 5-fluorouracil associated with fixed intravenous doses of bevacizumab, subcutaneous low doses of interleukin-2, and interferon-α-2a. An expanded cohort (phase II study) was treated at the recommended dose for additional safety and efficacy information according to minimax Simon two-stage design. Blood samples for Treg were collected and evaluated by fluorescence-activated cell sorting (FACS) analysis on cycle 1. Fifty-one patients were entered to receive one of five dose levels. Median age was 58 years (male 67 %, pretreated 49 %): 15 patients were low risk according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria, while 27 and nine were respectively intermediate- and high-risk patients. More frequent grade 3 and 4 toxicities included nonfebrile neutropenia, thrombocytopenia, and fever. Among patients evaluable for response (49), 29.5 % had partial response and 37 % stable disease. Overall median time to progression and median overall survival were 8.8 and 22.67 months, respectively. We observed a rapid increase in the percentage of Treg after immunotherapy and a reduction after bevacizumab only in patient who obtained a partial response or stable disease. The BIC was feasible, well tolerated, and shown interesting activity. Further studies are needed to explore if Treg could have a role in clinical response in mRCC treated with bevacizumab.
Collapse
Affiliation(s)
- M Donini
- Oncology Division, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100, Cremona, Italy,
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Bracarda S, Procopio G, Alesini D, Grillone F, Massari F, Zaniboni A, Mattioli R, Buti S, Garanzini E, Sisani M, Hamzaj A, Altavilla A, De Angelis V. Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e16058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Sergio Bracarda
- Medical Oncology, Ospedale San Donato USL8, Istituto Toscano Tumori (ITT), Arezzo, Italy
| | - Giuseppe Procopio
- Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Daniele Alesini
- Division of Medical Oncology, Università la Sapienza Roma, Rome, Italy
| | | | - Francesco Massari
- Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy
| | - Alberto Zaniboni
- Department of Medical Oncology, Casa di Cura Poliambulanza, Brescia, Italy
| | | | | | | | - Michele Sisani
- Department of Medical Oncology USL8, Arezzo, Arezzo, Italy
| | - Alketa Hamzaj
- Department of Medical Oncology, USL8 Arezzo, Arezzo, Italy
| | | | | |
Collapse
|
33
|
Gianlorenço ACL, Serafim KR, Canto-de-Souza A, Mattioli R. Effect of histamine H1 and H2 receptor antagonists, microinjected into cerebellar vermis, on emotional memory consolidation in mice. Braz J Med Biol Res 2014; 47:135-43. [PMID: 24519129 PMCID: PMC4051186 DOI: 10.1590/1414-431x20133429] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Accepted: 10/10/2013] [Indexed: 11/21/2022] Open
Abstract
This study investigated the effects of histamine H1 or H2 receptor antagonists on
emotional memory consolidation in mice submitted to the elevated plus maze (EPM). The
cerebellar vermis of male mice (Swiss albino) was implanted using a cannula guide.
Three days after recovery, behavioral tests were performed in the EPM on 2
consecutive days (T1 and T2). Immediately after exposure to the EPM (T1), animals
received a microinjection of saline (SAL) or the H1 antagonist chlorpheniramine (CPA;
0.016, 0.052, or 0.16 nmol/0.1 µL) in Experiment 1, and SAL or the H2 antagonist
ranitidine (RA; 0.57, 2.85, or 5.7 nmol/0.1 µL) in Experiment 2. Twenty-four hours
later, mice were reexposed to the EPM (T2) under the same experimental conditions but
they did not receive any injection. Data were analyzed using one-way ANOVA and the
Duncan test. In Experiment 1, mice microinjected with SAL and with CPA entered the
open arms less often (%OAE) and spent less time in the open arms (%OAT) in T2, and
there was no difference among groups. The results of Experiment 2 demonstrated that
the values of %OAE and %OAT in T2 were lower compared to T1 for the groups that were
microinjected with SAL and 2.85 nmol/0.1 µL RA. However, when animals were
microinjected with 5.7 nmol/0.1 µL RA, they did not show a reduction in %OAE and
%OAT. These results demonstrate that CPA did not affect behavior at the doses used in
this study, while 5.7 nmol/0.1 µL RA induced impairment of memory consolidation in
the EPM.
Collapse
Affiliation(s)
- A C L Gianlorenço
- Laboratório de Neurociências, Departamento de Fisioterapia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de São Carlos, São CarlosSP, Brasil, Laboratório de Neurociências, Departamento de Fisioterapia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de São Carlos, São Carlos, SP, Brasil
| | - K R Serafim
- Laboratório de Neurociências, Departamento de Fisioterapia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de São Carlos, São CarlosSP, Brasil, Laboratório de Neurociências, Departamento de Fisioterapia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de São Carlos, São Carlos, SP, Brasil
| | - A Canto-de-Souza
- Laboratório de Psicologia da Aprendizagem, Departamento de Psicologia, Centro de Educação e Ciências Humanas, Universidade Federal de São Carlos, São CarlosSP, Brasil, Laboratório de Psicologia da Aprendizagem, Departamento de Psicologia, Centro de Educação e Ciências Humanas, Universidade Federal de São Carlos, São Carlos, SP, Brasil
| | - R Mattioli
- Laboratório de Neurociências, Departamento de Fisioterapia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de São Carlos, São CarlosSP, Brasil, Laboratório de Neurociências, Departamento de Fisioterapia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de São Carlos, São Carlos, SP, Brasil
| |
Collapse
|
34
|
Veccia A, Burgio SL, di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Zustovich F, Mattioli R, Mansueto G, Facchini G, Procopio G, D'Angelo A, Spizzo G, Donini M, Bortolus R, Vicario G, Zucali PA, Basso U, Lo Re G, Caffo O. Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.4_suppl.92] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
92 Background: Docetaxel (DOC) represents the treatment of choice in the first line treatment for patients (pts) with castration-resistant prostate cancer (CRPC). However, when CRPC is diagnosed in pts age 80 or older, the fear of high toxicity degree usually limits chemotherapy use due to both pts frailty and several comorbidities occurrence. The present retrospective study is aimed to assess the clinical outcomes in this very elderly CRPC population. Methods: In this multicentric retrospective study, after Ethical Committee approval, we have reviewed the clinical records of all pts age 80 and older CRPC pts from participating institutions, treated with DOC in clinical practice, recording the pre- and post-DOC clinical history, the DOC treatment details and outcomes. Results: To date we collected a consecutive series of 115 pts from 28 Italian hospitals. The median age was 82 (range 80 to 90). The median baseline prostate-specific antigen (PSA) was 92 ng/ml (range 3 to 2,981); 83% of the pts had bone metastases, while nodal, lung and liver metastases were observed in 39%, 9%, and 8% of the pts, respectively. Median Cumulative Illness Rating Scale score was 3 (range 0 to 11), median Activity Daily Living index score was 0 (range 0 to 5), median Instrumental Activities of Daily Living score was 0 (range 0 to 5). The DOC was administered on 3 week or weekly schedule basis (43%/57%). A PSA reduction greater than 50% was observed in 55% of the pts; an objective response was observed in 15% of the 60 pts who underwent a radiological re-evaluation at the treatment end. Grade 3-4 toxicities were: anemia (2%), neutropenia (10%) , thrombocytopenia (2%), fatigue (10%), diarrhea (4%), nausea (2%), renal (2%), and febrile neutropenia (2%). The median progression-free survival (PFS) and overall survival (OS )were 7 months and 20 months, while the 1 year PFS and OS rates were 21.2% and 71.5%, respectively. Conclusions: This data suggests that selected very older (age 80 and older) CRPC pts may received DOC with a good toxicity profile. In this pts population the treatment, both on 3 week or weekly schedule, is able to produce survival outcomes comparable to pivotal trials (18 months).
Collapse
Affiliation(s)
| | - Salvatore Luca Burgio
- IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | | | - Cinzia Ortega
- Fondazione del Piemonte per l'Oncologia-Institute for Cancer Research and Treatment, Candiolo (Turin), Italy
| | | | - Michele Aieta
- IRCCS CROB Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
| | - Fable Zustovich
- Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padova, Italy
| | | | | | | | | | | | | | | | | | - Giovanni Vicario
- Ospedale San Giacomo Apostolo - Medical Oncology, Castelfranco Veneto, Italy
| | | | - Umberto Basso
- Medical Oncology 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy
| | - Giovanni Lo Re
- Santa Maria Degli Angeli General Hospital, Pordenone, Italy
| | | | | |
Collapse
|
35
|
Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Cartenì G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di Lorenzo G. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol 2013; 10:975-83. [PMID: 24295376 DOI: 10.2217/fon.13.256] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIM Cabazitaxel is a novel taxane that is approved for use in metastatic castration-resistant prostate cancer based on the Phase III TROPIC study, which showed improved overall survival with cabazitaxel/prednisone versus mitoxantrone/prednisone. A global early-access program was initiated in order to provide early access to cabazitaxel in docetaxel-pretreated patients and to obtain real-world data. PATIENTS & METHODS We report interim safety results from an Italian prospective, single-arm, multicenter, open-label trial of 218 patients receiving cabazitaxel 25 mg/m2 every 3 weeks plus prednisolone 10 mg/day, until disease progression, unacceptable toxicity, investigator's decision or death. RESULTS Patients completing treatment received a median of six cabazitaxel cycles. The most common grade 3/4 adverse events were neutropenia (33.9%), leukopenia (15.6%), anemia (6%) and asthenia (6%). No peripheral neuropathy or nail disorders were observed. CONCLUSION These results confirm that cabazitaxel has a manageable safety profile in daily clinical practice and support its use in patients with prostate cancer who progress during or after a docetaxel-based therapy.
Collapse
Affiliation(s)
- Sergio Bracarda
- Medical Oncology Unit, Department of Oncology, San Donato Hospital, 52100 Arezzo, Italy; Department of Oncology USL8, Istituto Toscano Tumori (ITT), San Donato Hospital, Via Pietro Nenni 20, 52100 Arezzo, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Costa J, Serafim KR, Gianlorenço ACL, Mattioli R. Low-dose thioperamide injected into the cerebellar vermis of mice immediately after exposure to the elevated plus-maze impairs their avoidance behavior on re-exposure to the apparatus. Braz J Med Biol Res 2013; 46:943-948. [PMID: 24270913 PMCID: PMC3854336 DOI: 10.1590/1414-431x20133179] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2013] [Accepted: 08/15/2013] [Indexed: 02/06/2023] Open
Abstract
The present study investigated the effect of thioperamide (THIO), an H3 histaminergic receptor antagonist, microinjected into the cerebellar vermis on emotional memory consolidation in male Swiss albino mice re-exposed to the elevated plus-maze (EPM). We implanted a guide cannula into the cerebellar vermis using stereotactic surgery. On the third day after surgery, we performed behavioral tests for two consecutive days. On the first day (exposure), the mice (n=10/group) were exposed to the EPM and received THIO (0.06, 0.3, or 1.5 ng/0.1 µL) immediately after the end of the session. Twenty-four hours later, the mice were re-exposed to the EPM under the same experimental conditions, but without drug injection. A reduction in the exploration of the open arms upon re-exposure to the EPM (percentage of number of entries and time spent in open arms) compared with the initial exposure was used as an indicator of learning and memory. One-way analysis of variance (ANOVA) followed by the Duncan post hoc test was used to analyze the data. Upon re-exposure, exploratory activity in the open arms was reduced in the control group, and with the two highest THIO doses: 0.3 and 1.5 ng/0.1 µL. No reduction was seen with the lowest THIO dose (0.06 ng/0.1 µL), indicating inhibition of the consolidation of emotional memory. None of the doses interfered with the animals' locomotor activity. We conclude that THIO at the lowest dose (0.06 ng/0.1 µL) microinjected into the cerebellum impaired emotional memory consolidation in mice.
Collapse
Affiliation(s)
- J Costa
- Laboratório de Neurociências, Departamento de Fisioterapia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de São Carlos, São Carlos,SP, Brasil
| | | | | | | |
Collapse
|
37
|
Gianlorenço ACL, Canto-de-Souza A, Mattioli R. Intra-cerebellar microinjection of histamine enhances memory consolidation of inhibitory avoidance learning in mice via H2 receptors. Neurosci Lett 2013; 557 Pt B:159-64. [PMID: 24161893 DOI: 10.1016/j.neulet.2013.10.017] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2013] [Revised: 09/26/2013] [Accepted: 10/06/2013] [Indexed: 11/15/2022]
Abstract
Studies have demonstrated the relationship between the histaminergic system and the cerebellum, and we intend to investigate the role of the cerebellar histaminergic system on memory consolidation. This study investigated the effect of intra-cerebellar microinjection of histamine on memory retention of inhibitory avoidance in mice, and the role of H1 and H2 receptors in it. The cerebellar vermis of male mice were implanted with guide cannulae, and after three days of recovery, the inhibitory avoidance test was performed. Immediately after a training session, animals received a microinjection of histaminergic drugs: in the experiment 1, saline (SAL) or histamine (HA 0.54, 1.36, 2.72 or 4.07 nmol); experiment 2, SAL or 1.36 nmol HA 5 min after a pretreatment with 0.16 nmol chlorpheniramine (CPA) or SAL; and experiment 3, SAL or 1.36 nmol HA 5 min after a pretreatment with 2.85 nmol ranitidine (RA) or SAL. Twenty-four hours later, a retention test was performed. The data were analyzed using one-way analysis of variance (ANOVA) and Duncan's tests. In experiment 1, animals microinjected with 1.36 nmol HA showed a higher latency to cross to the dark compartment compared to controls and to 2.72 and 4.07 nmol HA groups. In experiment 2, the combined infusions revealed difference between control (SAL+SAL) and SAL+HA and CPA+HA; while in the experiment 3 the analysis indicated differences in retention latency between mice injected with SAL+SAL and SAL+HA. The groups that received the H2 antagonist RA did not show difference compared to control. These results indicate that 1.36 nmol HA enhances memory consolidation of inhibitory avoidance learning in mice and that the pretreatment with H2 antagonist RA was able to prevent this effect.
Collapse
Affiliation(s)
- A C L Gianlorenço
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, 13565-905, Sao Carlos, Brazil.
| | | | | |
Collapse
|
38
|
Pinto C, Di Fabio F, Rosati G, Lolli I, Ruggeri E, Ciuffreda L, Ferrari D, Tumolo S, Rosti G, Tralongo P, Ferrara R, Alabiso O, Chiara S, Ianniello GP, Di Costanzo F, Frassoldati A, Iacono C, Adamo V, Mattioli R, Valeri M. Management of skin toxicity and cetuximab-based regimen compliance in first-line chemotherapy of metastatic colorectal cancer (mCRC) patients (pts): Results of observer study. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e14557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14557 Background: Cetuximab significantly improves efficacy when added to chemotherapy in mCRC pts. The ObservEr Study evaluated quality of life (QoL), skin toxicity management and treatment compliance of cetuximab-based regimens in first-line treatment of mCRC pts. Methods: ObservEr is a non-interventional, multicenter, prospective study. Primary endpoint is change in QoL during first-line treatment, with focus on the impact of dermatological toxicity. QoL (Dermatology Life Quality Index/DLQI and EORTC QLQ C30) is assessed at baseline and weekly for the first 8 weeks of treatment, then at every evaluation visit until PD or withdrawal. Secondary endpoints are efficacy, rate of liver metastasis resections, incidence of serious adverse events. Results: Between Apr 2011 and Nov 2012, 29 Italian centers enrolled 233 pts, with 226 evaluable pts. Pt characteristics: 152(67.3%) males, 74(32.7%) females; median age 65 (39-81) years; PS ECOG 0-1 95.5%; potentially resectable liver metastasis 59(27.1%); irinotecan regimens 129(57.1%), oxaliplatin regimens 60(26.5%), other regimens 37(16.4%). Median interval between request and result of KRAS test was 10 (6-15) days. Prophylactic skin treatment with vitamin K1 cream was used in 159(70.4%) pts, reactive treatment included vitamin K1 in 59(26.1%). Grade (gr) 1-2 skin toxicity was observed in 128(56.6%) pts, gr 3 in 28(12.4%); no gr 4 was detected. No significant difference in gr 3 skin toxicity was observed between males vs females (13.8 vs 9.5%; p=0.351), age <60 vs ≥60 years (18.1 vs 9.7%; p=0.077), irinotecan vs oxaliplatin regimens (12.4 vs 18.3%; p=0.278), prophylactic vs reactive treatment (15.1 vs 6.8%; p=0.339). Dose reduction, temporary and permanent discontinuation of cetuximab due to skin toxicity was required in 9(4.0%), 32(14.2%) and 7(3.1%) pts respectively; cetuximab compliance ≥70% of dose was reached in 208(92.0%) pts. Conclusions: These results suggest that appropriate skin toxicity management and prophylactic or reactive treatment with Vitamin K1 cream can improve the gr 3 skin toxicity control and the cetuximab compliance. QoL results will be shown at the 2013 ASCO Meeting. Clinical trial information: ID239.
Collapse
Affiliation(s)
- Carmine Pinto
- Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy
| | | | - Gerardo Rosati
- Medical Oncology Unit, S. Carlo Hospital, Potenza, Italy
| | - Ivan Lolli
- Medical Oncology Unit, IRCCS Saverio de Bellis, Castellana Grotte, Italy
| | - Enzo Ruggeri
- Medical Oncology Unit, Belcolle Hospital, Viterbo, Italy
| | | | - Daris Ferrari
- Medical Oncology Unit, San Paolo Hospital, Milan, Italy
| | - Salvatore Tumolo
- Medical Oncology Department, S. Maria degli Angeli Hospital, Pordenone, Italy
| | - Giovanni Rosti
- Medical Oncology Unit, St.Maria di Cà Foncello Hospital, Treviso, Italy
| | - Paolo Tralongo
- Medical Oncology Unit, G Di Maria Hospital, Avola, Italy
| | | | - Oscar Alabiso
- Medical Oncology Unit, Maggiore della Carità Hospital, Novara, Italy
| | - Silvana Chiara
- Medical Oncology Unit, National Cancer Institute, Genoa, Italy
| | | | | | | | - Carmelo Iacono
- Medical Oncology Unit, M.Paternò Hospital, Ragusa, Italy
| | - Vincenzo Adamo
- Unit of Medical Oncology, A.O. Papardo; Department of Human Pathology, University of Messina, Messina, Italy
| | | | - Michele Valeri
- Medical Oncology Unit, General Hospital, Macerata, Italy
| |
Collapse
|
39
|
Serafim KR, Kishi MS, Canto-de-Souza A, Mattioli R. H₁ but not H₂ histamine antagonist receptors mediate anxiety-related behaviors and emotional memory deficit in mice subjected to elevated plus-maze testing. Braz J Med Biol Res 2013; 46:440-6. [PMID: 23598647 PMCID: PMC3854398 DOI: 10.1590/1414-431x20132770] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Accepted: 02/08/2013] [Indexed: 11/22/2022] Open
Abstract
This study investigated the role of H1 and H2 receptors in
anxiety and the retrieval of emotional memory using a Trial 1/Trial 2 (T1/T2)
protocol in an elevated plus-maze (EPM). Tests were performed on 2 consecutive
days, designated T1 and T2. Before T1, the mice received intraperitoneal
injections of saline (SAL), 20 mg/kg zolantidine (ZOL, an H2
receptor antagonist), or 8.0 or 16 mg/kg chlorpheniramine (CPA, an
H1 receptor antagonist). After 40 min, they were subjected
to the EPM test. In T2 (24 h later), each group was subdivided into two
additional groups, and the animals from each group were re-injected with SAL or
one of the drugs. In T1, the Student t-test showed no
difference between the SAL and ZOL or 8 mg/kg CPA groups with respect to
the percentages of open arm entries (%OAE) and open arm time
(%OAT). However, administration of CPA at the highest dose of
16 mg/kg decreased %OAE and %OAT, but not locomotor
activity, indicating anxiogenic-like behavior. Emotional memory, as revealed by
a reduction in open arm exploration between the two trials, was observed in all
experimental groups, indicating that ZOL and 8 mg/kg CPA did not affect
emotional memory, whereas CPA at the highest dose affected acquisition and
consolidation, but not retrieval of memory. Taken together, these results
suggest that H1 receptor, but not H2, is implicated in
anxiety-like behavior and in emotional memory acquisition and consolidation
deficits in mice subjected to EPM testing.
Collapse
Affiliation(s)
- K R Serafim
- Laboratório de Neurociências, Departamento de Fisioterapia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de São Carlos, São Carlos, SP, Brasil
| | | | | | | |
Collapse
|
40
|
Montanari M, Fabbri F, Rondini E, Frassineti GL, Mattioli R, Carloni S, Scarpi E, Zoli W, Amadori D, Cruciani G. Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori 2013. [PMID: 23389354 DOI: 10.1700/1217.13491] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS AND BACKGROUND Non-pegylated liposomal doxorubicin (NPLD) (Myocet) has shown marked in vitro activity in castration-resistant prostate cancer (CRPC) and also in docetaxel-resistant cells, higher than that shown by pegylated liposomal doxorubicin. Its activity would seem to be due to a high intracellular drug concentration and induction of Golgi-dependent apoptosis. On the basis of these results, a clinical study was designed to assess the activity of NPLD and low-dose prednisone in second-line therapy. METHODS Fifty-four patients were enrolled and evaluated. Eligibility criteria were histologically confirmed CRPC, PSA >20 ng/mL or measurable lesions according to the RECIST criteria, previous docetaxel-based chemotherapy, and adequate cardiac function. Patients were treated with weekly intravenous NPLD 25 mg/m2 and daily prednisone 10 mg until progression. RESULTS Median patient age was 69 years (range, 52-83) and median baseline PSA concentration was 120 ng/mL (range, 5.35-4350). Sixteen (29.6%) patients had measurable lesions. Objective or PSA responses (>50% reduction) were observed in 8 (14.8%) patients. The median time to progression was 2.8 months and the median overall survival was 11.3 months. Toxicity was generally mild (grade 1-2) and infrequent, with grade 3-4 neutropenia in 12.9% of cases. Grade 3 nonhematological toxicities included nausea in 2 patients (3.7%) and fatigue and stomatitis in 1 case (1.9%). No drug-related serious adverse events were reported. CONCLUSIONS Weekly administration of NPLD is a well tolerated treatment with proven albeit limited activity.
Collapse
Affiliation(s)
- Marco Montanari
- Oncology Unit, Santa Maria delle Croci Hospital, Viale Randi 5, Ravenna, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Bracarda S, Marchetti P, Gasparro D, Gernone A, Boccardo F, Messina C, Gianni L, Bortolus R, Fratino L, Fornarini G, Carteni G, Tucci M, Mazzanti R, Scotto T, Martoni A, Basso U, Procopio G, Morelli F, Mattioli R, Di Lorenzo G. Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.6_suppl.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
189 Background: A significant percentage of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) progressing during or after a docetaxel (D) based therapy are candidates for additional effective treatments. Taxanes remain the mainstay of treatment for a wide range of tumours including mCRPC. Cabazitaxel, a next generation of taxane, was approved based on results from the TROPIC study (NCT00417079). Cbz plus prednisone (P) was associated with a higher overall survival than mitoxantrone (MTX) (15.1 vs 12.7 mo, HR=0.70; P<0.0001). Moreover CbzP was associated with clinical benefits, better PFS, maintenance of ECOG PS, improved tumour and PSA response, longer time to tumour and PSA progression while pain control was similar to MTX. These clear benefits supported a global EAP. Methods: Here we report, the preliminary safety analysis of 165 pts entered in the study from 25 Italian centres between Jan and Nov 2011. Pts received Cbz 25 mg/m2(intravenous every 3 weeks) plus P 10 mg (oral daily). Results: Median age was 70 years (21.8% of the cases were ≥75 years); pts with PS 0-1=98.2%; median number of previous D cycles was 8; 30.8% received 450 ÷ 675 mg, 14.7% received 675 ÷ 900 mg and 28.2% received ≥ 900 mg of D. Median time from last D dose to first CbzP dose was 5 months including any other eventual chemotherapy treatment. 49.1% of the pts entered in this EAP because refractory to D (PD during or within 3 months since the last D administration), overall 72 % of pts had 2 or more met sites. At the time of this analysis approximately 50% of pts received 4 cycles. A total of 68 pts discontinued CbzP due to PD (38.2%), AEs related and not related (38.2)%, Investigator’s decision (2.9%) or other reasons (20.6%). The most common G 3/4 AEs were neutropenia (35.2%), leukopenia (17.6%), anaemia (5.5%) febrile neutropenia (4.2%); main non-haematological AEs were asthenia (4.8%) and fatigue (4.2%). Conclusions: This large analysis confirms a manageable safety profile of cabazitaxel in routine clinical practice. The safety profile showed in EAP study suggests cabazitaxel a safe and effective treatment option in mCRPC pts progressing during or after a docetaxel based therapy. Clinical trial information: NCT01254279.
Collapse
Affiliation(s)
- Sergio Bracarda
- Department of Oncology, USL-8, Ospedale San Donato, Arezzo, Italy
| | - Paolo Marchetti
- Oncology Department, Azienda Ospedaliera S. Andrea, Roma, Italy
| | | | - Angela Gernone
- Azienda Ospedaliera Universitaria Consorziale Policlinico, Bari, Italy
| | - Francesco Boccardo
- Oncology Department, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | - Luca Gianni
- Fondazione San Raffaele del Monte Tabor, Milan, Italy
| | | | | | | | | | - Marcello Tucci
- Medical Oncology, Department of Clinical and Biological Sciences, A.O.U. San Luigi Gonzaga, Orbassano, Italy
| | | | - Tiziana Scotto
- Presidio Ospedaliero Ospedale Civile SS. Annunziata, Sassari, Italy
| | - Andrea Martoni
- Medical Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy
| | - Umberto Basso
- Medical Oncology 1, Istituto Oncologico Veneto-IRCCS, Padova, Italy
| | | | - Franco Morelli
- Medical Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | | | - Giuseppe Di Lorenzo
- Department of Clinical Oncology and Endocrinology and Rare Tumors Reference Center Campania Region, University Federico II, Naples, Italy
| |
Collapse
|
42
|
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial. J Clin Oncol 2012; 30:4501-7. [DOI: 10.1200/jco.2012.43.6758] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Purpose To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). Primary end point was progression-free survival (PFS). A preplanned pooled analysis of the results of this study with those of the NVALT7 study was carried out to assess the impact of carboplatin added to pemetrexed in terms of overall survival (OS). Results From July 2007 to October 2009, 239 patients (arm A, n = 120; arm B, n = 119) were enrolled. Median PFS was 3.6 months for arm A versus 3.5 months for arm B (hazard ratio [HR], 1.05; 95% CI, 0.81 to 1.36; P = .706). No statistically significant differences in response rate, OS, or toxicity were observed. A total of 479 patients were included in the pooled analysis. OS was not improved by the addition of carboplatin to pemetrexed (HR, 90; 95% CI, 0.74 to 1.10; P = .316; P heterogeneity = .495). In the subgroup analyses, the addition of carboplatin to pemetrexed in patients with squamous tumors led to a statistically significant improvement in OS from 5.4 to 9 months (adjusted HR, 0.58; 95% CI, 0.37 to 0.91; P interaction test = .039). Conclusion Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. The benefit observed with carboplatin addition in squamous tumors may warrant further investigation.
Collapse
Affiliation(s)
- Andrea Ardizzoni
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Marcello Tiseo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Luca Boni
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Andrew D. Vincent
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Rodolfo Passalacqua
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Sebastiano Buti
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Domenico Amoroso
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Andrea Camerini
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Roberto Labianca
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Giovenzio Genestreti
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Corrado Boni
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Libero Ciuffreda
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Francesco Di Costanzo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Filippo de Marinis
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Lucio Crinò
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Antonio Santo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Antonio Pazzola
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Fausto Barbieri
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Nicoletta Zilembo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Ida Colantonio
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Carmelo Tibaldi
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Rodolfo Mattioli
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Mara A. Cafferata
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Roberta Camisa
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Egbert F. Smit
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| |
Collapse
|
43
|
Silva MCD, Mattioli R, Lessa H, Zanchet M, Blois C. Physical exercise and chronic orthopedic pain: A study with retirees elderly. J Sci Med Sport 2012. [DOI: 10.1016/j.jsams.2012.11.700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Serafim KR, Gianlorenço ACL, Daher FP, Mattioli R. H1-histamine receptors in the amygdala are involved in emotional memory but do not mediate anxiety-related behaviors in mice submitted to EPM testing. Brain Res Bull 2012; 89:1-7. [PMID: 22772356 DOI: 10.1016/j.brainresbull.2012.06.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2012] [Revised: 06/19/2012] [Accepted: 06/22/2012] [Indexed: 11/28/2022]
Affiliation(s)
- K R Serafim
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, Rod. Washington Luis, Sao Carlos, Brazil.
| | | | | | | |
Collapse
|
45
|
Testa L, Agnifili M, Latini RA, Mattioli R, Lanotte S, De Marco F, Oreglia J, Latib A, Pizzocri S, Laudisa ML, Brambilla N, Bedogni F. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM 2012; 105:949-57. [PMID: 22771555 DOI: 10.1093/qjmed/hcs114] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND Vit-K antagonists are the therapy of choice to prevent thromboembolic events due to atrial fibrillation since many years. New oral anticoagulants (NOA) showed encouraging results vs. warfarin but there are no data directly comparing different NOA. We performed an adjusted indirect meta-analysis. METHODS Randomized controlled trials (RCTs) were searched. Efficacy end points were the cumulative rate of thomboembolic stroke (TES) and systemic embolism (SE). Main safety end point was the rate of hemorrhagic stroke (HS). RESULTS Three RCTs (50578 patients) were included. Overall, NOA were comparable to warfarin according to the cumulative risk of TES and SE, as well as for TES alone. NOA were associated with a reduced rate of SE [OR 0.64 (0.44, 0.94], P=0.02]. Compared to warfarin, NOA were associated with a significantly reduced risk of HS [OR 0.43 (0.34, 0.55), P<0.001, NNT to avoid a HS 153] and all cause death [OR 0.90 [0.84, 0.96], P=0.03, NNT to save one fatality 43]. Head to head comparison showed that in terms of cumulative rate of TES/SE, as well as of TES, none of the NOA was significantly superior to the others (all Ps>0.05). Rivaroxaban showed superiority in the prevention of SE. Dabigatran 150 mg/twice daily was associated with the largest reduction in the risk of HS vs. warfarin and vs. other NOA. Overall mortality was quite comparable across NOA. CONCLUSION Overall superiority of NOA over warfarin is largely influenced by the reduction of HS. Dabigatran 150 mg/twice daily seems to have the best risk/benefit profile.
Collapse
Affiliation(s)
- L Testa
- Department of Cardiology, Clinical Institute S. Ambrogio, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Gianlorenço ACL, Serafim KR, Canto-de-Souza A, Mattioli R. Emotional memory consolidation impairment induced by histamine is mediated by H1 but not H2 receptors. Brain Res Bull 2012; 89:197-202. [PMID: 22986235 DOI: 10.1016/j.brainresbull.2012.09.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2012] [Revised: 09/02/2012] [Accepted: 09/04/2012] [Indexed: 10/27/2022]
Abstract
Histaminergic fibers are present in the molecular and granular layers of the cerebellum and have high density in the vermis and flocculus. Evidence indicates that the cerebellar vermis is involved in memory consolidation. Recently, we demonstrated that when histamine is microinjected into the cerebellar vermis it results in impaired emotional memory consolidation in mice that are submitted to the elevated plus maze (EPM). This study investigated whether histamine impairment was mediated by the H(1) or H(2) receptors. The cerebellar vermis of male mice (Swiss Albino) were implanted using a guide cannula. Three days after recovery, behavioral tests were performed in the EPM on two consecutive days (Trial 1 and Trial 2). Immediately after exposure to the EPM (Trial 1), animals received a microinjection of histaminergic drugs. In Experiment 1, saline (SAL) or histamine (HA, 4.07 nmol/0.1 μl) was microinjected 5 min after pretreatment with the H(1) antagonist chlorpheniramine (CPA, 0.16 nmol/0.1μl) or SAL. In Experiment 2, SAL or HA was microinjected into the mice 5 min after pretreatment with the H(2) antagonist ranitidine (RA, 2.85 nmol/0.1 μl) or SAL. Twenty-four hours later, the mice were re-exposed to the EPM (Trial 2) under the same experimental conditions but did not receive an injection. On both days, the test sessions were recorded to enable analysis of the behavioral measures. The decrease in open arm exploration (% entries and % time spent in the open arms) in Trial 2 relative to Trial 1 was used as a measure of learning and memory. The data were analyzed using the two-way analysis of variance (ANOVA) and Duncan's tests. In Experiment 1, the Duncan's test indicated that the mice entered the open arms less often (%OAE) and spent less time in the open arms (%OAT) in Trial 2 after being microinjected with SAL+SAL, SAL+CPA and CPA+HA. However, the animals that received SAL+HA did not enter the open arms less frequently or spend less time in them, which was significantly different from the CPA+HA group. The results of Experiment 2 demonstrated that the %OAE and %OAT in Trial 2 were different from Trial 1 for the groups that were microinjected with SAL+SAL and SAL+RA. The animals that were microinjected with RA+HA or with SAL+HA did not show a reduction in %OAE. These results demonstrate that the animals treated with HA did not avoid the open arms less on retesting and indicated that CPA did not alter the behavior parameters but did revert the histamine-induced impairment of memory consolidation. Furthermore, the H(2) antagonist RA, at the dose used in this study, did not affect memory consolidation and failed to revert histamine-induced impairment.
Collapse
Affiliation(s)
- A C L Gianlorenço
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences, and Health, Federal University of São Carlos, Rodovia Washington Luís, São Carlos, Brazil
| | | | | | | |
Collapse
|
47
|
Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori 2012. [PMID: 22322832 DOI: 10.1700/1018.11082] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Anthracycline-containing regimens have demonstrated significant disease-free and overall survival benefits in the adjuvant setting and also provide palliative benefit in metastatic disease. . Over the past two decades, an increasing proportion of patients have been exposed to adjuvant anthracyclines with concomitant reduction in their use for palliation, as a result of concerns regarding efficacy and cumulative anthracycline-associated cardiotoxicity, as well as the availability of other systemic chemotherapeutic options. This report reflects the consensus view of a meeting of oncologists, pharmacologists and cardiologists held in Florence, Italy, on April 30, 2010. The objectives of the meeting were to review the role and limits of conventional anthracyclines in the treatment of breast cancer, to provide recommendations for the use of novel anthracycline formulations, such as non-pegylated liposomal doxorubicin (NPLD), and to identify potential future indications for NPLD that warrant further research.
Collapse
Affiliation(s)
- Mario Airoldi
- SC Oncologia Medica 2, Presidio Ospedaliero San Giovanni Antica Sede, Turin, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Savona M, Mattioli R, Nigro S, Falasca G, Della Rovere F, Costantino P, De Vries S, Ruffoni B, Trovato M, Altamura MM. Two SERK genes are markers of pluripotency in Cyclamen persicum Mill. J Exp Bot 2012; 63:471-88. [PMID: 21976770 DOI: 10.1093/jxb/err295] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The genetic basis of stem cell specification in somatic embryogenesis and organogenesis is still obscure. SOMATIC EMBRYOGENESIS RECEPTOR-LIKE KINASE (SERK) genes are involved in embryogenesis and organogenesis in numerous species. In vitro culture of Cyclamen persicum immature ovules provides a system for investigating stem cell formation and maintenance, because lines forming either organs or embryos or callus without organs/embryos are available for the same cultivar and plant growth regulator conditions. The present aim was to exploit this property of cyclamen cultures to understand the role of SERK(s) in stem cell formation and maintenance in somatic embryogenesis and organogenesis in vitro, in comparison with expression in planta. CpSERK1 and CpSERK2 were isolated from embryogenic callus. CpSERK1 and CpSERK2 levels by RT-PCR showed that expression is high in embryogenic, moderate in organogenic, and null in recalcitrant calli. in situ hybridizations showed that the expression of both genes started in clumps of pluripotent stem cells, from which both pre-embryogenic aggregates and organ meristemoids derived, and continued in their trans-amplifying, meristem-like, derivatives. Expression declined in organ meristemoids, in parallel with a partial loss of meristematization. In mature somatic embryos, and in shoot and root primordia, CpSERK1 and CpSERK2 were expressed in meristems, and similar patterns occurred in zygotic embryo and primary meristems in planta. The results point to SERK1 and SERK2 as markers of pluripotency in cyclamen. It is proposed that the high expression of these genes in the trans-amplifying derivatives of the stem cells maintains a pluripotent condition leading to totipotency and, consequently, somatic embryogenesis.
Collapse
Affiliation(s)
- M Savona
- 'Sapienza' University of Rome, Dept. of Environmental Biology, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Imperatori L, Lippe P, Trapuzzano C, Laid G, Cappelletti C, Tamburrano T, Mattioli R. 5075 POSTER Non-pegylated Liposomal Doxorubicin (Myocet e) Plus Docetaxel (Taxotere e) (MYTAX), as First-line Chemotherapy (CHT), in Metastatic Breast Cancer (MBC): Results of a Phase II Study. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71517-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Gianlorenço ACL, Canto-de-Souza A, Mattioli R. Microinjection of histamine into the cerebellar vermis impairs emotional memory consolidation in mice. Brain Res Bull 2011; 86:134-8. [PMID: 21664441 DOI: 10.1016/j.brainresbull.2011.05.014] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2011] [Revised: 05/24/2011] [Accepted: 05/26/2011] [Indexed: 11/19/2022]
Abstract
The biogenic amine histamine is an important neurotransmitter in the central nervous system that has been implicated in learning and memory processes. Experimental evidence indicates that the role of the cerebellum may be more complex than the simple regulation of motor responses, and recent studies have demonstrated significant involvement of the cerebellum in emotional memory consolidation. This study investigated the effect of histamine microinjected into the cerebellar vermis on emotional memory consolidation in mice in the elevated plus-maze (EPM). The cerebellar vermis of male mice (Swiss Albino) were implanted with guide cannulae. The mice weighed between 25 and 30 g. After three days of recovery, behavioral tests in the EPM were performed on two consecutive days; the testing periods were called, Trial 1 and Trial 2. Immediately after Trial 1, the animals received microinjections of histamine in the cerebellar vermis (0.54, 1.36, 2.72, and 4.07 nmol/0.1 μl). On both days, the test sessions were recorded to enable analysis of behavioral measures. The decrease in open arm exploration (% entries and % time spent in the open arms) in Trial 2 relative to Trial 1 was used as a measure of learning and memory. The data were analyzed using One-way Analysis of Variance (ANOVA) and Duncan's tests. The percentage of open arm entries (%OAE) and the percentage of time spent in the open arms (%OAT) were reduced in Trial 2 relative to Trial 1 for the control group; the same was true for the group that was microinjected with histamine at doses of 0.54 (%OAE and %OAT) and 1.36 nmol (%OAT). However, when the animals received histamine at doses of 2.72 and 4.07 nmol, their open arm exploration did not decrease. No significant changes were observed in the number of enclosed arm entries (EAE), an EPM index of general exploratory activity. These results suggest that there is a dose-dependent inhibitory effect of histamine microinjected into the cerebellar vermis on emotional memory consolidation.
Collapse
Affiliation(s)
- A C L Gianlorenço
- Laboratory of Neuroscience, Physiotherapy Department, Center of Biological Sciences and Health, Federal University of Sao Carlos, Brazil
| | | | | |
Collapse
|